

UNIVERSIDADE FEDERAL DE MINAS GERAIS
Faculdade de Medicina
Programa de Pós-Graduação em Ciências Aplicadas à Cirurgia e à
Oftalmologia

ANA LUIZA COSME SILVA

**SUPER EXPRESSÃO DO RECEPTOR DE INOSITOL 1-4-5-
TRISFOSFATO ISOFORMA 3 (ITPR3) EM
COLANGIOCARCINOMAS E SUA CORRELAÇÃO COM A
PROTEÍNA DEPENDENTE DE CÁLCIO S100A4.**

Belo Horizonte

2023

Ana Luiza Cosme Silva

**SUPER EXPRESSÃO DO RECEPTOR DE INOSITOL 1-4-5-
TRISFOSFATO ISOFORMA 3 (ITPR3) EM
COLANGIOCARCINOMAS E SUA CORRELAÇÃO COM A
PROTEÍNA DEPENDENTE DE CÁLCIO S100A4.**

Dissertação apresentada ao Programa de Pós-graduação em Ciências Aplicadas à Cirurgia e à Oftalmologia da Faculdade de Medicina da Universidade Federal de Minas Gerais, como requisito parcial para a obtenção do grau de Mestre.

Orientador: Prof. Vivian Resende

Coorientador: Michele Angela Rodrigues

Belo Horizonte – MG

2023

SI586s Silva, Ana Luiza Cosme.
Superexpressão do receptor de Inositol 1,4,5-trifosfato isoforma 3 (ITPR3) em Colangiocarcinoma e sua correlação com a proteína dependente de cálcio S100A4 [recursos eletrônicos]. / Ana Luiza Cosme Silva. - - Belo Horizonte: 2023.
51f.: il.
Formato: PDF.
Requisitos do Sistema: Adobe Digital Editions.

Orientador (a): Vivian Resende.
Coorientador (a): Michele Angela Rodrigues.
Área de concentração: Bases Moleculares e Fisiopatológicas de Neoplasias.
Dissertação (mestrado): Universidade Federal de Minas Gerais, Faculdade de Medicina.

1. Receptores de Inositol 1,4,5-Trifosfato. 2. Proteína A4 de Ligação a Cálcio da Família S100. 3. Colangiocarcinoma. 4. Neoplasias. 5. Fígado. 6. Dissertação Acadêmica. I. Resende, Vivian. II. Rodrigues, Michele Angela. III. Universidade Federal de Minas Gerais, Faculdade de Medicina. IV. Título.

NLM: WI 765



FOLHA DE APROVAÇÃO

**ANÁLISE IMUNOHISTOQUÍMICA DOS RECEPTORES DO TIPO 3-
INOSITOL 1-4-5-TRIFOSFATO (ITPR3) DO FATOR DE
CRESCIMENTO EPIDÉRMICO (EGFR) E DA PROTEÍNA A4 DE
LIGAÇÃO DE CÁLCIO S100 (S100A4) EM COLANGIOCARCINOMA.**

ANA LUIZA COSME SILVA

Dissertação submetida à Banca Examinadora designada pelo Colegiado do Programa de Pós-Graduação em CIÊNCIAS APLICADAS À CIRURGIA E À OFTALMOLOGIA, como requisito para obtenção do grau de Mestre em CIÊNCIAS APLICADAS À CIRURGIA E À OFTALMOLOGIA, área de concentração ANATOMOFISIOPATOGENIA CIRÚRGICA, linha de pesquisa Bases Moleculares e Fisiopatológicas de Neoplasias.

Aprovada em 22 de março de 2023, pela banca constituída pelos membros:

Prof(a). Vivian Resende - Orientador
Universidade Federal de Minas Gerais

Prof(a). Michele Angela Rodrigues
UFMG

Prof(a). Eduardo Paulino Junior
UFMG

Prof(a). Leonardo do Prado Lima
HC-UFMG

Belo Horizonte, 22 de março de 2023.

Para aqueles que acreditam na Ciência e persistem
buscando pelo conhecimento.

AGRADECIMENTOS

À minha orientadora, professora Dra. Vivian Resende pelos ensinamentos valiosos e por guiar meu desenvolvimento no campo científico.

À Dra. Michele Ângela Rodrigues do Laboratório de Imunologia e Bioquímica e Imunobiologia do Instituto de Ciências Biológicas da UFMG pela parceria na realização dessa pesquisa.

Ao Dr. Dawidson Assis Gomes pelas contribuições nas análises estatísticas e imuno histoquímicas.

À Coordenação de Aperfeiçoamento de Pessoal de Nível Superior do Brasil (CAPES) e ao Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) pelo incentivo e fomento a essa pesquisa.

A todos os mestres e colegas do Programa de Pós-Graduação de Ciências Aplicadas à Cirurgia e à Oftalmologia da Faculdade de Medicina da UFMG, pelos ensinamentos e contribuições para a minha formação.

À minha filha Olívia Carolina Cosme Carvalho que me impulsiona todos os dias a buscar o melhor de mim.

Às minhas queridas irmãs Raquel Cosme Silva e Carolina Cosme Silva pelo apoio incondicional e encorajamento.

À Luciene Carla Gomes pela amizade e escuta empática diante dos desafios.

Aos meus pais, Marta Célia Cosme Silva e Marconi Silva por serem meu maior exemplo de força, renúncia e dedicação. Todas as minhas conquistas dedicarei a vocês.

RESUMO

O colangiocarcinoma (CCA) é a segunda neoplasia mais maligna do fígado que surge na árvore biliar. O CCA está associado com mau prognóstico e os principais fatores envolvidos em sua patogênese não são bem compreendidos. Os receptores tirosina quinases (RTKs), como o receptor do fator de crescimento epidérmico (EGFR), podem mediar as vias de sinalização de cálcio intracelular (Ca^{2+}), via inositol 1,4,5-trifosfato (InsP3). Eles ativam os receptores 1,4,5-trifosfato (ITPRs) e regulam o crescimento tumoral. ITPR isoforma 3 é o principal canal de liberação intracelular de Ca^{2+} em colangiócitos. Os efeitos do Ca^{2+} intracelular, por sua vez, são mediados por proteínas de ligação de cálcio, como calmodulina e proteína A4 de ligação de cálcio S100 (S100A4). No entanto, o significado clínico patológico e biológico de EGFR, ITPR3 e S100A4 no CCA permanece obscuro. Assim, o presente trabalho investiga a imunexpressão dessas três proteínas em 59 pacientes diagnosticados com CCA, submetidos a tratamento cirúrgico curativo e correlaciona os dados com características clínico-patológicas e sobrevida. A alta expressão de ITPR3 foi correlacionada com os níveis de CA 19-9, estágio TNM e metástases em linfonodos (N). Além disso, a expressão de ITPR3 foi aumentada em CCA distal em comparação com ductos biliares de controle e CCAs intra-hepáticos e peri-hilares. Os escores clínicos ITPR3 e S100A4 foram significativamente correlacionados. Em resumo, a super expressão de ITPR3 pode contribuir para a progressão da CCA e pode representar um potencial alvo terapêutico.

Palavras-chave: ITPRs; ITPR3; S100A4; Colangiocarcinoma; Fígado; Câncer

ABSTRACT

Cholangiocarcinoma (CCA) is the second most malignant neoplasm in the liver that arises from the biliary tree. CCA is associated with a poor prognosis, and the key players involved in its pathogenesis are still not well understood. Receptor tyrosine kinases (RTKs), such as epidermal growth factor receptor (EGFR), can mediate intracellular calcium (Ca^{2+}) signaling pathways via inositol 1,4,5-trisphosphate (InsP3), activating inositol 1,4,5-trisphosphate receptors (ITPRs) and regulating tumor growth. ITPR isoform 3 (ITPR3) is the main intracellular Ca^{2+} release channel in cholangiocytes. The effects of intracellular Ca^{2+} are mediated by calcium-binding proteins such as Calmodulin and S100 calcium-binding protein A4 (S100A4). However, the clinicopathological and biological significance of EGFR, ITPR3 and S100A4 in CCA remains unclear. Thus, the present work investigates the immunoexpression of these three proteins in 59 CCAs from patients who underwent curative surgical treatment and correlates the data with clinicopathological features and survival. High ITPR3 expression was correlated with CA 19-9 levels, TNM stage and lymph node metastasis (N). Furthermore, ITPR3 expression was increased in distal CCA compared to control bile ducts and intrahepatic and perihilar CCAs. In summary, ITPR3 overexpression could contribute to CCA progression and it may represent a potential therapeutic target.

Keywords: ITPRs; ITPR3; S100A4; Cholangiocarcinoma; Liver; Cancer

LISTA DE FIGURAS

- Figura 1** - Classificação do CCA de acordo com a posição anatômica e imunohisquímica para o ITPR3 em CCA's intra-hepático, peri-hilar e distal.14
- Figura 2** - Histologia hepática de pacientes com CCA e controles. Fotomicrografias representativas de amostras de fígado de controles e pacientes com CCA intra-hepático, peri-hilar e distal coradas com hematoxilina e eosina (H&E) **(A)** Corte do fígado mostrando um parênquima hepático normal com um trato portal de aparência normal. **(B)** Corte de CCA inter-hepático mostrando muitas estruturas glandulares com perfis arredondados e irregulares. **(C)** Corte de CCA peri-hilar mostrando um tipo de crescimento papilar. **(D)** Corte de CCA distal mostrando um tipo de crescimento papilar.23
- Figura 3** - Imunohistoquímica representando a expressão alta/positiva e baixa/negativa das três proteínas. Expressão alta/positiva de ITPR3 (73,6%), S100A4 (8,7%) e EGFR (31,58%) e expressão baixa/negativa de ITPR3 (26,32%), S100A4 (91,23%) e EGFR (68,42%).24
- Figura 4** - Imunohistoquímica para o ITPR3 em CCA humano com ductos biliares de controle (setas pretas). e pacientes com CCAs intra-hepáticos, peri-hilares e distais. A coloração é intensa em CCA's distais.....25
- Figura 5** - Probabilidade de sobrevivência em pacientes com CCA após ressecção. **(A)** Estimativas da curva de sobrevida de Kaplan-Meier para pacientes com CCA com expressão baixa/negativa e alta/positiva de ITPR3, EGFR e S100A4, após ressecção cirúrgica. **(B)** Para o ITPR3, os tempos médios de sobrevida foram 19 e 40 meses ($p=0,4715$). **(C)** Para S100A4, os tempos médios de sobrevida foram 19 e 40 meses ($p=0,2773$). **(D)** Para S100A4, os tempos médios de sobrevida foram 18 e 30 meses ($p= 0,1948$).....29

LISTA DE TABELA

Tabela 1 – Relação entre ITPR3, S100A4, EGFR e características clínico-patológicas em casos de colangiocarcinoma humano.	27
--	-----------

LISTA DE ABREVIATURAS E SIGLAS

CA19-9	Antígeno carboidrato
CAAE	Certificado de Apresentação de Apreciação Ética
CCA	Colangiocarcinoma
CCA's	Colangiocarcinomas
EGF	Fator de Crescimento Epidermal
EGFR	Receptor de Fator de Crescimento Epidermal
H2O2	Peróxido de Hidrogênio
HCl	Ácido Clorídrico
IHQ	Imuno histoquímica
InsP3	Inositol 1,4,5-trifosfato
ITPR3	Receptor de Inositol 1,4,5-trifosfato
S100A4	Proteína de ligação de cálcio
TNM	Sistema TNM de Classificação de Tumores Malignos

SUMÁRIO


1. INTRODUÇÃO	14
2. RELEVÂNCIA	16
3. OBJETIVOS	17
4. MÉTODO	18
4.1. Seleção de pacientes e estudos anatomopatológicos	18
4.2. Marcação imuno histoquímica	18
4.3. Análise imuno histoquímica	19
4.4. Análises estatísticas	21
5. RESULTADOS	22
5.1. Expressão do ITPR3, EGFR e S100A4 em CCA primário	22
5.2. Correlação entre a expressão de ITPR3, S100A4 e EGFR e características clínico-patológicas.	26
5.3. Análise de sobrevida	28
6. DISCUSSÃO	30
7- CONCLUSÃO	33
8. REFERÊNCIAS	34

1.INTRODUÇÃO

O colangiocarcinoma (CCA) constitui um grupo raro de doenças malignas que acometem a árvore biliar. CCA's são classificados de acordo com sua posição anatômica, podendo ser: intra-hepático, peri-hilar e distal (Figura 1). Possui histogênese heterogênea com origem a partir de diferentes células como as progenitoras hepáticas, colangiócitos, hepatócitos e células tronco (Banales *et al.*, 2020; Rizvi *et al.*, 2018). No entanto, sua manifestação clínica, história natural, fatores de risco e genéticos podem interferir na resposta à quimioterapia. Apesar de muitos avanços na área, os mecanismos de carcinogênese ainda são mal compreendidos (Banales *et al.*, 2019, 2020).

A colangiocarcinogênese é orquestrada por uma complexa interação de ligantes, tais como citocinas pró-inflamatórias e fatores de crescimento. Estudos imuno histoquímicos (IHQ) têm mostrado que receptores de fatores de crescimento podem ser superexpressos em amostras de CCA humano (Harder *et al.*, 2009). Tal como o receptor de fator de crescimento epidermal (EGFR), que é um receptor do tipo tirosina quinase codificado por proto-oncogenes. O EGFR foi relatado por desempenhar um papel fundamental no ciclo celular, migração e angiogênese (Mahipal *et al.*, 2018). A superexpressão desse receptor pode estar relacionada à colangiocarcinogênese em CCA, com alto nível de expressão no subtipo intra-hepático (Pignochino *et al.*, 2010). Além disso, a ativação de EGFR por seu ligante EGF também ativa a sinalização de Ca^{2+} via Inositol 1,4,5-trifosfato (InsP3), ativando o receptor de inositol 1,4,5-trifosfato (Miranda, De *et al.*, 2019).

Figura 1 - Classificação do CCA de acordo com a posição anatômica e imuno hisquímica para o ITPR3 em CCA's intra-hepático, peri-hilar e distal. (Rodrigues et al., 2022)



As vias de sinalização de Ca^{2+} , por sua vez, regulam diversos processos tais como: crescimento tumoral, proliferação celular, apoptose, migração celular, transcrição genética e necrose. Em colangiócitos, a liberação de Ca^{2+} no citosol, ocorre principalmente por meio do receptor de inositol 1,4,5-trifosfato tipo 3 (ITPR3) (Hirata e Nathanson, 2001; Rodrigues *et al.*, 2007). Estudos anteriores demonstraram que esta isoforma está envolvida com a biologia de CCA (Gomes *et al.*, 2021). Além disso, a expressão de ITPR3 é envolvida na patogênese de outras neoplasias e sua superexpressão está correlacionada com outros tipos de câncer (Hedberg *et al.*, 2016; Kang *et al.*, 2010).

Os efeitos do cálcio intracelular são mediados por proteínas de ligação de cálcio e têm sido relacionados a um pior prognóstico e agressividade tumoral em pacientes com diferentes tipos de carcinoma, incluindo o colorretal, esofágico, bexiga, pâncreas, estômago e mama (Nedjadi *et al.*, 2018; Xu *et al.*, 2014). A proteína S100A4, uma proteína de ligação de cálcio, contém dois domínios de ligação “EF-hand” e ela foi reconhecida por desempenhar um papel fundamental na progressão do tumor e metástase (Park, Jung e Koo, 2016). Esta molécula regula muitos efeitos biológicos intracelulares e extracelulares, incluindo proliferação celular, remodelação da matriz extracelular, descolamento celular e angiogênese (Boye e Mælandsmo, 2010; Tian *et al.*, 2015).

Trabalhos anteriores demonstram a expressão de S100A4 como marcador útil para prever progressão, metástase e prognóstico do CCA como um gene relacionado à metástase (Fabris *et al.*, 2011). Recentemente, a expressão de S100A4 foi detectada em CCA intra-hepático e a sua expressão nuclear foi identificada como um forte preditor de metástase e redução da sobrevida após a ressecção (Tian *et al.*, 2015).

Este estudo teve como objetivo investigar a expressão de ITPR3, S100A4 e EGFR e sua correlação com as características clínico-patológicas de CCA's intra e extra-hepáticos. Foi avaliada a associação entre ITPR3, S100A4, EGFR e a sobrevida pós-operatória dos pacientes.

2.RELEVÂNCIA

O estudo da biologia molecular dos Colangiocarcinomas, com identificação de potenciais alvos para o tratamento quimioterápico, é essencial para tornar possível a seleção de pacientes que podem se beneficiar do tratamento com fármacos específicos.

Ainda não há na literatura estudos que correlacionam a expressão EGFR, ITPR3 e a proteína S110A4 em CCA, o que pode contribuir para um progresso no entendimento da fisiopatologia dos CCA's.

3. OBJETIVOS

- Analisar o grau de expressão imuno histoquímica (IHQ) do receptor EGFR e das proteínas de ligação ITPR3 e S100A4 em colangiocarcinomas.
- Correlacionar a expressão destes biomarcadores com os dados clínico patológicos dos pacientes verificando se há relação entre grau de expressão e pior prognóstico em diferentes tipos de CCA.

4. MÉTODO

4.1. Seleção de pacientes e estudos anatomopatológicos

No período entre Janeiro de 2008 a Março de 2021 foram coletadas um total de 59 amostras de pacientes submetidos a ressecção cirúrgica com intenção curativa para tratamento de CCA. O Comitê de Ética Institucional aprovou esta pesquisa (número de referência :CAAE - 37156714.6.0000.5149). Foram coletados dados referentes ao sexo, idade, histórico de tabagismo ou alcoolismo, localização, origem anatômica. Além de achados clínicos como expressão do CA- 19-9 (carboidrato antígeno), o tipo histológico, estágio tumoral, invasão angiovascular, margem cirúrgica e sobrevida após o tratamento.

Para a classificação e o estadiamento foi seguido o padrão TNM do American Joint Committee/Union for International Cancer Control. Para ajuste de possíveis efeitos na sobrevida relacionados a complicações cirúrgicas, pacientes que morreram durante os primeiros 30 dias após a cirurgia foram excluídos. Assim, o período de acompanhamento iniciou-se 30 dias após a ressecção do tumor, variando de 2 a 60 meses (mediana 21,78 meses). As relações entre ITPR3, S100A4 e EGFR e as características clínico patológicas de CCA humano são relatados na Tabela 1.

4.2. Marcação imuno histoquímica

Os anticorpos primários usados para análise IHQ foram anti-EGFR (1:100, clone 31G7, Invitrogen, California, USA); ITPR3 (1:100 monoclonal, BD Biosciences, Rockville, MD, USA) e S100A4 (1:200, polyclonal, Invitrogen). O processamento seguiu-se como descrito anteriormente, com pequenas modificações (Rodrigues *et al.*, 2021).

Em resumo, para coloração ITPR3 e S100A4, cortes com espessura de 4 µm de tumores foram transferidos para lâminas sinalizadas, e os tecidos, fixados em formol e embebidos em parafina (FFPE), foram posteriormente desparafinizados, reidratados, seguido por recuperação antigênica em solução Trilogy (Cell Marque,

Koclin, CA , EUA) com aquecimento pressurizado (125 °C) por 20 min de acordo com as instruções do fabricante.

Foi realizado a recuperação enzimática de EGFR usando 0,1% de pepsina em 10 mM de HCl (Sigma-Aldrich, St. Louis, MO, EUA) a 37 C° por 30 min. As lâminas foram desparafinizadas em xileno (Sigma-Aldrich), e a atividade da peroxidase endógena foi extinta com 3% de H₂O₂ em metanol (Sigma-Aldrich). Em seguida, as lâminas foram cobertas com blocos de proteína sem soro (Dako, Santa Clara, CA, EUA) por 30 min e depois incubados com os anticorpos primários (EGFR, ITPR3 e S100A4) durante a noite a 4 C°. Foi aplicado manualmente um sistema de detecção baseado em peroxidase, Novolink™ Polymer (Leica Biosystems Newcastle Ltd., New Castle, Reino Unido).

A imunorreatividade foi visualizada incubando-se as lâminas por 2 minutos com 3,3'diaminobenzidina (sistema de substrato Lab Vision DAB; Lab Vision, Fremont, Califórnia, EUA). Os controles negativos foram preparados omitindo o anticorpo primário. Para o controle positivo foi usado o tecido hepático não tumoral adjacente.

4.3. Análise imuno histoquímica

Dois observadores independentes avaliaram o grau de imunorreação nos cortes histológicos de forma cega. Foram selecionados aleatoriamente cinco campos de grande aumento (40×) de cada corte para avaliar a porcentagem de células tumorais marcadas e a intensidade de marcação. A expressão de EGFR foi avaliada em amostras de CCA usando os escores definidos de acordo com o consenso da Sociedade Americana de Oncologia Clínica e do Colégio de Patologistas Americanos (ASCO/CAP; Wolff et al.). Como segue:

- 0 = não coloração de membrana ou coloração de membrana incompleta e fraca/pouco perceptível em ≤ 10% das células tumorais;
- 1 = incompleta e fraca/pouca coloração perceptível da membrana em ≥ 10% das células tumorais;

- 2 = incompleta e/ou coloração de membrana fraca/moderada em > 10% das células tumorais ou coloração completa e intensa da membrana em ≤ 10% das células tumorais;
- 3 = coloração completa e intensa da membrana em > 10% das células tumorais.

Espécimes com pontuação de 0, 1 e 2 foram considerados como negativo, e aqueles com pontuação 3 foram considerados como alto/positivo (Wolff *et al.*, 2013, 2018).

O método de pontuação utilizado por Silveira *et al.* para prostaglandina G/H sintase 2 (COX2) foi adaptado para pontuação ITPR3 e S100A4 (Lavalle *et al.*, 2009; Silveira *et al.*, 2020). O número de células positivas para ITPR3 e S100A4 foi avaliado de forma semiquantitativa, com o escore de distribuição definido pela estimativa da porcentagem de células positivas em cinco campos com ampliação de 40x, da seguinte forma:

- 0 = ausência;
- 1 = menos de 10% de células coradas;
- 2 = entre 10% e 30%; 3 = entre 31% e 60%;
- 4 = mais de 61% de células coradas.

Para a intensidade de coloração, os valores variaram de 0 a 3 como segue:

- 0 = ausência;
- 1 = coloração fraca;
- 2 = coloração moderada;
- 3 = forte coloração.

A pontuação de distribuição e a intensidade foram multiplicadas para obter uma pontuação total, que variou de 0 a 12. Para avaliar a expressão de S100A4, a coloração no citoplasma e/ou núcleos foi considerada positiva.

4.4. Análises estatísticas

Diferenças no escore de IHQ e nos níveis de marcadores tumorais, dependendo localização foram analisados usando o teste de Kruskal-Wallis e o teste U de Mann-Whitney. A análise estatística das curvas de sobrevida e o modelo de regressão de riscos proporcionais de Cox foram realizados usando os métodos sobrevida do software RStudio (versão 1.4,1717; versão R em execução:4.10). Os testes do qui-quadrado e exato de Fisher foram usados para analisar a correlação entre a expressão de ITPR3, S100A4 e EGFR e as características clínico-patológicas de pacientes com CCA. De acordo com análise de sobrevivência de Kaplan-Meier, o teste log-rank foi usado para comparar a sobrevida global dos pacientes. Valores de $p < 0.05$ foram considerados estatisticamente significativos.

5. RESULTADOS

5.1. Expressão do ITPR3, EGFR e S100A4 em CCA primário.

Primeiro, a relação da expressão de ITPR3, EGFR e S100A4 em CCA foi examinada em amostras de fígado de pacientes com CCA intra-hepático (n = 17), peri-hilar (n = 29) e distal (n = 17). Os diagnósticos histológicos foram estabelecidos com base no exame de espécimes coradas com hematoxilina-eosina (H&E) (Fig. 2A-D).

As taxas de ITPR3, EGFR e a expressão de S100A4 foi de 73,6%, 31,58% e 8,7%. Já as taxas de baixa expressão foram 26,32%, 68,42% e 91,23%, respectivamente (Fig. 3). Imagens representativas de coloração alta/positiva e baixa/negativa para cada proteína é mostrada na Fig. 3.

A expressão relativa de ITPR3 foi examinada de acordo com a origem anatômica do tumor. A marcação IHQ de ITPR3 aumentou ao comparar ductos biliares de controle com CCA's intra-hepáticos, peri-hilares e distais ($p < 0,05$ e $p < 0,0001$, respectivamente) (Fig. 4B). Nenhuma diferença de marcação foi observada entre CCA intra-hepático e peri-hilar (Fig. 4B). Esse resultado foi confirmado quando comparando a expressão de ITPR3 de acordo com a pontuação IHQ (Fig. 4C e D). A expressão aumentada de ITPR3 no CCA distal comparado com a CCA intra-hepática foi confirmado pelo escore IHQ ($p < 0,05$) (Fig. 4C e D).

A coloração IHQ de seções de fígado controle mostrou que a expressão de ITPR3 em colangiócitos estava concentrada na área apical do ducto biliar, como foi descrito anteriormente (Hirata *et al.*, 2002). Juntos, esses resultados demonstram que a expressão de ITPR3 está aumentada em CCA e sua super expressão é especialmente pronunciada em pacientes com CCA distal.

Figura 2 - Histologia hepática de pacientes com CCA e controles. Fotomicrografias representativas de amostras de fígado de controles e pacientes com CCA intra-hepático, peri-hilar e distal coradas com hematoxilina e eosina (HeE) (A) Corte do fígado mostrando um parênquima hepático normal com um trato portal de aparência normal. (B) Corte de CCA intra-hepático mostrando muitas estruturas glandulares com perfis arredondados e irregulares. (C) Corte de CCA peri-hilar mostrando um tipo de crescimento papilar. (D) Corte de CCA distal mostrando um tipo de crescimento papilar.




Figura 3 - Imunohistoquímica representando a expressão alta/positiva e baixa/negativa das três proteínas. Expressão alta/positiva de ITPR3 (73,6%), S100A4 (8,7%) e EGFR (31,58%) e expressão baixa/negativa de ITPR3 (26,32%), S100A4 (91,23%) e EGFR (68,42%).





Figura 4 - Imunohistoquímica para o ITPR3 em CCA humano com ductos biliares de controle (seta preta) em pacientes com CCAs intra-hepáticos, peri-hilares e distais. A coloração é intensa em CCA's distais.



5.2. Correlação entre a expressão de ITPR3, S100A4 e EGFR e características clínico-patológicas.

A análise do teste qui-quadrado mostrou que a expressão positiva de ITPR3 foi correlacionada com um valor CA 19-9 > 37 U/ml ($P = 0,049$) e metástase linfonodal ($P = 0,024$). A expressão positiva para S100A4 foi correlacionada com um alto grau histológico ($P = 0,024$), metástase linfonodal ($P = 0,009$) e margem cirúrgica ($P = 0,047$).

A expressão positiva de EGFR foi correlacionado com o estágio TNM ($P = 0,046$). Outros fatores, incluindo sexo, idade, tabagismo e uso de álcool, localização, histologia, invasão angiovascular e estágio T, não apresentaram correlação significativa com nenhuma das 3 proteínas analisadas (Tabela 1).

As correlações entre ITPR3, S100A4 e EGFR foram exploradas com o teste exato de Fisher. A expressão de ITPR3 foi correlacionada com a expressão de S100A4 ($p = 0,049$). Por outro lado, não houve correlação significativa entre a expressão de EGFR e a expressão das demais proteínas.

Tabela 1 – Relação entre ITPR3, S100A4, EGFR e características clínico-patológicas em casos de colangiocarcinoma humano.


Características clínicas	Casos N	ITPR3		P	S100A4		p	EGFR		p
		Negativo	Positivo		Negativo	Positivo		Negativo	Positivo	
Gênero										
Masculino	32	10	22		29	3		22	10	
Feminino	25	5	20	0.339	23	2	0.856	17	8	0.952
Idade (anos)										
≤ 60	27	5	22		24	3		17	10	
> 60	30	10	20	0.255	28	2	0.554	22	8	0.400
Tabagismo										
Sim	18	3	15		16	2		13	5	
Não	37	10	27	0.396	34	3	0.716	24	13	0.585
Etilismo										
Sim	16	4	12		15	1		12	4	
Não	41	11	30	0.888	37	4	0.674	27	14	0.504
CA 19-9										
≤ 37 U/ml	12	7	5		12	0		9	3	
> 37 U/ml	24	6	18	0.049	22	2	0.375	14	10	0.326
Localização										
Intra-hepático	14	6	8		14	0		7	7	
Extra-hepático	43	9	34	0.106	38	5	0.182	32	11	0.088
Histologia										
Papilar	15	4	11		14	1		10	5	
Outros	42	11	31	0.971	38	4	0.737	29	13	0.865
Invasão angiovascular										
Positivo	42	10	32		37	5		28	14	
Negativo	15	5	10	0.472	15	0	0.162	11	4	0.634
Grau Histológico										
G1	14	2	12		14	0		12	2	
G2	38	12	26		35	3		25	13	
G3	5	1	4	0.429	3	2	0.024	2	3	0.140
Metástase linfonodal										
Positivo	23	2	21		18	5		15	8	
Negativo	28	10	18	0.024	28	0	0.009	20	8	0.634
Estágio T										
T1+T2	34	9	25		33	1		26	8	
T3+T4	23	6	17	0.974	19	4	0.058	13	10	0.112
Estágio TNM										
I+II	31	9	22		30	1		25	6	
III+IV	25	6	19	0.673	21	4	0.096	14	11	0.046
Margem cirúrgica										
Positivo	22	8	14		18	4		15	7	
Negativo	35	7	28	0.172	34	1	0.047	24	11	0.975

5.3. Análise de sobrevida

A análise de sobrevida de Kaplan-Meier foi realizada nos 49 pacientes que não vieram a óbito por mais de um mês após a cirurgia (Fig. 5A). Durante o período de acompanhamento (1-60 meses), um total de 31 pacientes morreram (63,2%).

O tempo médio de sobrevivência com base em 49 indivíduos foi de 29 meses (95% intervalo de confiança [IC] = 18-43), conforme mostrado na Fig. 6. Para pacientes com baixa e alta expressão de ITPR3, os tempos médios de sobrevivência foram de 19 e 40 meses ($p = 0,4715$) (Fig. 5B). O tempo médio de sobrevivência foi de 19 e 40 meses ($p = 0,2773$) ao comparar pacientes com alta expressão de EGFR (Fig. 5C) e 18 e 30 ($p = 0,1948$) para pacientes com expressão de S100A4 baixa versus alta (Fig. 5D). A taxa de sobrevida geral comparando os níveis de expressão alta e baixa entre as 3 proteínas não mostraram diferença no estudo.

Figura 5 - Probabilidade de sobrevivência em pacientes com CCA após ressecção. (A) Estimativas da curva de sobrevida de Kaplan-Meier para pacientes com CCA com expressão baixa/negativa e alta/positiva de ITPR3, EGFR e S100A4, após ressecção cirúrgica. (B) Para o ITPR3, os tempos médios de sobrevida foram 19 e 40 meses ($p=0,4715$). (C) Para S100A4, os tempos médios de sobrevida foram 19 e 40 meses ($p=0,2773$). (D) Para S100A4, os tempos médios de sobrevida foram 18 e 30 meses ($p= 0,1948$).



6. DISCUSSÃO

O CCA é caracterizado por prognóstico ruim, invasão precoce e metástases disseminadas. No entanto, ainda faltam biomarcadores precisos para diagnosticar e estimar o prognóstico de pacientes com CCA. A ressecção cirúrgica continua sendo o principal tratamento potencialmente curativo para todos os três subtipos de doença e apenas uma pequena porcentagem de pacientes são elegíveis. Por isso, a investigação de novos marcadores subjacentes à progressão da CCA é de grande relevância para o diagnóstico e terapêutica (Banales *et al.*, 2020; Rizvi *et al.*, 2018; Rizvi e Gores, 2013).

Neste trabalho, estudamos a expressão de EGFR, ITPR3 e S100A4 em amostras de ressecção cirúrgica, correlacionando os resultados clínicos com essas três proteínas. Um estudo anterior demonstrou que o EGFR expresso em CCA foi associado com progressão e recorrência do tumor (Padthaisong *et al.*, 2020). A família EGFR é conhecida como uma proteína da família tirosina quinase, envolvida em muitos processos celulares, esta proteína ativa diversas vias de regulação (Miranda, De *et al.*, 2019; Padthaisong *et al.*, 2020). A ativação do EGFR pode iniciar a sinalização intracelular para a proliferação celular, migração, adesão e oncogênese (Angelis Campos, De *et al.*, 2011; Rodrigues *et al.*, 2016; Yarden e Pines, 2012).

Além disso, a expressão aumentada de EGFR e mutações em seu gene estão associadas com neoplasias como câncer de mama, glioblastomas, câncer de pulmão e carcinoma de células escamosas de cabeça e pescoço (Yarden e Pines, 2012). As proteínas da família EGF são usadas como potenciais biomarcadores para o prognóstico da doença e progressão em vários tumores (Arteaga e Engelman, 2014; Miyata *et al.*, 2017).

No presente estudo, a expressão de EGFR foi considerada positiva em 31,58% dos casos. A análise univariada mostrou maior taxa de expressão em tumores em estágios avançados, ocorrendo em 19,6% dos tumores estágio III + IV versus 10,7% dos tumores estágio I + II ($p = 0,046$). Exprimindo assim, características de um fenótipo agressivo na presença de doença invasiva.

O CCA é classificado em três subgrupos de acordo com suas características patológicas e estágios. Dependendo da localização, os CCA's apresentam diferentes graus de invasão em estruturas adjacentes, o que também pode influenciar no prognóstico (Ercolani *et al.*, 2015). A localização anatômica implica em diferentes desfechos de sobrevida, embora a expressão de EGFR não tenha apresentado diferença significativa entre as três localizações, conforme previamente descrito por nosso grupo (Gomes *et al.*, 2018).

A ativação de EGFR por EGF também ativa a sinalização de Ca^{2+} via InsP3, ativando ITPRs, e essa via de sinalização parece estar envolvida no crescimento tumoral (Miranda, De *et al.*, 2019). Em condições normais, o ITPR3 desempenha papel importante na mediação da secreção de bicarbonato em colangiócitos (Minagawa *et al.*, 2007). Estudos anteriores relatam que o ITPR3 diminui em condições coleostáticas (Shibao *et al.*, 2003). Este receptor está presente e concentrado na região apical do epitélio do ducto biliar humano e de roedores (Minagawa *et al.*, 2007). O tipo 3 ITPR é a principal isoforma em colangiócitos e novas evidências sugerem que ela pode desempenhar papel, particularmente, importante no câncer (Gomes *et al.*, 2021; Hirata *et al.*, 2002).

Trabalhos anteriores mostraram que a expressão de ITPR3 está envolvida na patogênese do carcinoma hepatocelular [47]. Também está associado à agressividade do carcinoma colorretal [14]. Ueasilamongkol *et al.* relataram superexpressão de ITPR3 em CCA's intra-hepáticos (n = 4) e hilares (n = 3) (Gomes *et al.*, 2021).

Nosso estudo examinou a expressão de ITPR3 em um número maior de pacientes (n = 59) com dados clínico-patológicos de acordo com as origens anatômicas dos três tipos de CCA. Descobrimos que a expressão de ITPR3 foi aumentada em pacientes com CCA distal em comparação com CCA intra-hepático e ductos biliares normais. O escore alto/positivo (por coloração IHQ) foi encontrado em 73,6% dos casos. Além disso, dependendo da origem anatômica, a expressão de ITPR3 foi aumentada em CCAs peri-hilares e distais em comparação com CCA's intra-hepático. A expressão alta/positiva de ITPR3 aumentou, significativamente, com os

níveis do marcador tumoral CA 19-9 em 50% dos pacientes ($p = 0,049$). A metastáse linfonodal foi alta em 41,1% dos casos ($p = 0,024$).

Os efeitos do aumento do cálcio via ITPR3 são mediados por proteínas de ligação ao cálcio, como a S100A4. Esta proteína tem sido proposta como um marcador útil para prever a progressão, metástase e prognóstico em CCA (Fabris *et al.*, 2011). A S100A4 localiza-se no citoplasma, núcleo e espaço extracelular e está envolvida em muitas etapas da cascata metastática, incluindo motilidade celular, invasão e angiogênese (Boye e Mælandsmo, 2010).

Estudos anteriores da expressão de S100A4 relataram que a sua superexpressão pode estar correlacionada com a agressividade do tumor e um mau prognóstico em outros tipos de carcinoma (Tsukamoto *et al.*, 2013). Neste estudo, a expressão positiva de S100A4 em CCA primários foi confirmada em 8,7% dos casos. No entanto, resultados anteriores indicaram que a S100A4 nuclear foi um forte preditor de metástase e redução da sobrevivência após a ressecção em pacientes com CCA (Fabris *et al.*, 2011).

Em nosso estudo, observamos expressão nuclear em apenas 3 casos. No entanto, na maioria dos nossos espécimes, houve expressão predominante no citoplasma, conforme observado por Zhang *et al.* (Tian *et al.*, 2015). Além disso, a coloração positiva em espécimes não se restringiu apenas a células tumorais porque níveis altamente expressos também foram detectados em tecidos tumorais/estromais. A expressão alta/positiva de S100A4 foi correlacionada com um alto grau histológico, metástase linfonodal e margem cirúrgica.

7- CONCLUSÃO

Nossos resultados demonstram que a expressão elevada de ITPR3 está correlacionada com achados clinico-patológicos, como CA 19-9, estágio TNM e metástase linfonodal (N). Além disso, a expressão de ITPR3 e S100A4 foi significativamente correlacionada. A expressão de ITPR3 está aumentada em CCA, e sua superexpressão é particularmente pronunciada em pacientes com CCA distal. Mais trabalhos serão necessários para entender melhor os fatores envolvidos no acúmulo de ITPR3 em CCA e determinar se esses fatores podem ser investigados para propostas terapêuticas.

8. REFERÊNCIAS

- ANGELIS CAMPOS, A. C. DE *et al.* Epidermal growth factor receptors destined for the nucleus are internalized via a clathrin-dependent pathway. **Biochemical and Biophysical Research Communications**, v. 412, n. 2, p. 341–346, 2011.
- ARTEAGA, C. L.; ENGELMAN, J. A. ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics. **Cancer Cell**, v. 25, n. 3, p. 282–303, mar. 2014.
- BANALES, J. M. *et al.* Cholangiocyte pathobiology. **Nature Reviews Gastroenterology and Hepatology**, v. 16, n. 5, p. 269–281, 2019.
- _____. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. **Nature Reviews Gastroenterology and Hepatology**, v. 17, n. 9, p. 557–588, 2020.
- BOYE, K.; MÆLANDSMO, G. M. S100A4 and metastasis: A small actor playing many roles. **American Journal of Pathology**, v. 176, n. 2, p. 528–535, 2010.
- ERCOLANI, G. *et al.* Intrahepatic, peri-hilar and distal cholangiocarcinoma: Three different locations of the same tumor or three different tumors? **European Journal of Surgical Oncology**, v. 41, n. 9, p. 1162–1169, 2015.
- FABRIS, L. *et al.* Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastasization. **Hepatology**, v. 54, n. 3, p. 890–899, 2011.
- GOMES, D. A. *et al.* Type 3 inositol 1,4,5-trisphosphate receptor is increased and enhances malignant properties in cholangiocarcinoma. **Hepatology**, v. 71, n. 2, p. 583–599, 2021.
- GOMES, R. V. *et al.* Expression of epidermal growth factor receptor (EGFR) in cholangiocarcinomas: Predictive factors and survival. **Revista do Colegio Brasileiro de Cirurgioes**, v. 45, n. 3, p. 1–9, 2018.
- HARDER, J. *et al.* EGFR and HER2 expression in advanced biliary tract cancer. **World Journal of Gastroenterology**, v. 15, n. 36, p. 4511–4517, 2009.
- HEDBERG, M. L. *et al.* Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. **Journal of Clinical Investigation**, v. 126, n. 1, p. 169–180, 2016.
- HIRATA, K. *et al.* Regulation of Ca²⁺ signaling in rat bile duct epithelia by inositol 1,4,5-trisphosphate receptor isoforms. **Hepatology**, v. 36, n. 2, p. 284–296, 2002.


- HIRATA, K.; NATHANSON, M. H. Bile duct epithelia regulate biliary bicarbonate excretion in normal rat liver. **Gastroenterology**, v. 121, n. 2, p. 396–406, 2001.
- KANG, S. S. *et al.* Caffeine-mediated inhibition of calcium release channel inositol 1,4,5-trisphosphate receptor subtype 3 blocks glioblastoma invasion and extends survival. **Cancer Research**, v. 70, n. 3, p. 1173–1183, 2010.
- LAVALLE, G. E. *et al.* Cox-2 expression in canine mammary carcinomas: Correlation with angiogenesis and overall survival. **Veterinary Pathology**, v. 46, n. 6, p. 1275–1280, 2009.
- MAHIPAL, A. *et al.* **Novel targeted treatment options for advanced cholangiocarcinoma.** [s.l.] Taylor & Francis, 2018. v. 27
- MINAGAWA, N. *et al.* Cyclic AMP Regulates Bicarbonate Secretion in Cholangiocytes Through Release of ATP Into Bile. **Gastroenterology**, v. 133, n. 5, p. 1592–1602, 2007.
- MIRANDA, M. C. DE *et al.* Epidermal growth factor (EGF) triggers nuclear calcium signaling through the intranuclear phospholipase C-4 (PLC4). **Journal of Biological Chemistry**, v. 294, n. 45, p. 16650–16662, 2019.
- MIYATA, K. *et al.* Serum heparin-binding epidermal growth factor-like growth factor (HB-EGF) as a biomarker for primary ovarian cancer. **Anticancer Research**, v. 37, n. 7, p. 3955–3960, 2017.
- NEDJADI, T. *et al.* S100A8 and S100A9 proteins form part of a paracrine feedback loop between pancreatic cancer cells and monocytes. **BMC Cancer**, v. 18, n. 1, p. 1–8, 2018.
- PADTHAISONG, S. *et al.* A panel of protein kinase high expression is associated with postoperative recurrence in cholangiocarcinoma. **BMC Cancer**, v. 20, n. 1, p. 1–16, 2020.
- PARK, C. K.; JUNG, W. H.; KOO, J. S. Expression of cancer-associated fibroblast-related proteins differs between invasive lobular carcinoma and invasive ductal carcinoma. **Breast Cancer Research and Treatment**, v. 159, n. 1, p. 55–69, 2016.
- PIGNOCHINO, Y. *et al.* Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. **BMC Cancer**, v. 10, n. 1, p. 631, 2010.
- RIZVI, S. *et al.* Cholangiocarcinoma-evolving concepts and therapeutic strategies. **Nature Reviews Clinical Oncology**, v. 15, n. 2, p. 95–111, 2018.

- RIZVI, S.; GORES, G. J. Pathogenesis, diagnosis, and management of cholangiocarcinoma. **Gastroenterology**, v. 145, n. 6, p. 1215–29, dez. 2013.
- RODRIGUES, M. A. *et al.* Nucleoplasmic Calcium Is Required for Cell Proliferation. **Journal of Biological Chemistry**, v. 282, n. 23, p. 17061–17068, jun. 2007.
- _____. Inner nuclear membrane localization of epidermal growth factor receptor (EGFR) in spontaneous canine model of invasive micropapillary carcinoma of the mammary gland. **Pathology - Research and Practice**, v. 212, n. 4, p. 340–344, abr. 2016.
- _____. Characterization of neoplastic cells outlining the cystic space of invasive micropapillary carcinoma of the canine mammary gland. **BMC Veterinary Research**, v. 17, n. 1, p. 1–13, 2021.
- RODRIGUES, M. A. *et al.* Biomedicine & Pharmacotherapy cholangiocarcinoma and its expression correlates with S100 calcium-binding protein A4 (S100A4). v. 145, n. August 2021, 2022.
- SHIBAO, K. *et al.* Basic–liver, pancreas, and biliary tract. v. 5085, n. 03, p. 1175–1187, 2003.
- SILVEIRA, T. L. *et al.* Cyclooxygenase-2 expression is associated with infiltration of inflammatory cells in oral and skin canine melanomas. **Veterinary and Comparative Oncology**, v. 18, n. 4, p. 727–738, 2020.
- TIAN, X. *et al.* The Expression of S100A4 Protein in Human Intrahepatic Cholangiocarcinoma: Clinicopathologic Significance and Prognostic Value. **Pathology and Oncology Research**, v. 21, n. 1, p. 195–201, 2015.
- TSUKAMOTO, N. *et al.* The expression of S100A4 in human pancreatic cancer is associated with invasion. **Pancreas**, v. 42, n. 6, p. 1027–1033, 2013.
- WOLFF, A. C. *et al.* Recommendations for human epidermal growth factor receptor 2 testing in breast. **Journal of Clinical Oncology**, v. 31, n. 31, p. 3997–4013, 2013.
- _____. HER2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update summary. **Journal of Oncology Practice**, v. 14, n. 7, p. 437–441, 2018.
- XU, C. *et al.* S100A14, a member of the EF-hand calcium-binding proteins, is overexpressed in breast cancer and acts as a modulator of HER2 signaling. **Journal of Biological Chemistry**, v. 289, n. 2, p. 827–837, 2014.
- YARDEN, Y.; PINES, G. The ERBB network: At last, cancer therapy meets systems biology. **Nature Reviews Cancer**, v. 12, n. 8, p. 553–563, 2012.



Contents lists available at ScienceDirect

Biomedicine & Pharmacotherapy

journal homepage: www.elsevier.com/locate/bioph

Inositol 1,4,5-trisphosphate receptor type 3 (ITPR3) is overexpressed in cholangiocarcinoma and its expression correlates with S100 calcium-binding protein A4 (S100A4)

Michele A. Rodrigues^a, Dawidson A. Gomes^b, Ana Luiza Cosme^c, Marcelo Dias Sanches^{c,d}, Vivian Resende^{c,d,1}, Giovanni D. Cassali^{a,*,1}

^a Department of General Pathology, Universidade Federal de Minas Gerais, Av. Antônio Carlos 6627, Belo Horizonte, Minas Gerais CEP 31270-901, Brazil

^b Department of Biochemistry and Immunology, Universidade Federal de Minas Gerais, Av. Antônio Carlos 6627, Belo Horizonte, Minas Gerais CEP 31270-901, Brazil

^c School of Medicine, Department of Surgery, Universidade Federal de Minas Gerais, Av. Prof. Alfredo Balena 190, Belo Horizonte, Minas Gerais CEP 30130-100, Brazil

^d Hepatopancreatobiliary Division, Clinical Hospital, Universidade Federal de Minas Gerais, Av. Prof. Alfredo Balena 110, Belo Horizonte, Minas Gerais CEP 30130-100, Brazil

ARTICLE INFO

Keywords:
ITPRs
ITPR3
S100A4
Cholangiocarcinoma
Liver
Cancer

ABSTRACT

Cholangiocarcinoma (CCA) is the second most malignant neoplasm in the liver that arises from the biliary tree. CCA is associated with a poor prognosis, and the key players involved in its pathogenesis are still not well understood. Receptor tyrosine kinases (RTKs), such as epidermal growth factor receptor (EGFR), can mediate intracellular calcium (Ca^{2+}) signaling pathways via inositol 1,4,5-trisphosphate (InsP3), activating inositol 1,4,5-trisphosphate receptors (ITPRs) and regulating tumor growth. ITPR isoform 3 (ITPR3) is the main intracellular Ca^{2+} release channel in cholangiocytes. The effects of intracellular Ca^{2+} are mediated by calcium-binding proteins such as Calmodulin and S100 calcium-binding protein A4 (S100A4). However, the clinicopathological and biological significance of EGFR, ITPR3 and S100A4 in CCA remains unclear. Thus, the present work investigates the immunorexpression of these three proteins in 59 CCAs from patients who underwent curative surgical treatment and correlates the data with clinicopathological features and survival. High ITPR3 expression was correlated with CA 19-9 levels, TNM stage and lymph node metastasis (N). Furthermore, ITPR3 expression was increased in distal CCA compared to control bile ducts and intrahepatic and perihilar CCAs. These observations were confirmed by proteomic analysis. ITPR3 and S100A4 clinical scores were significantly correlated. Furthermore, it was demonstrated that EGF induces calcium signaling in a cholangiocarcinoma cell line and ITPR3 colocalizes with nonmuscle myosin IIA (NMIIA). In summary, ITPR3 overexpression could contribute to CCA progression and it may represent a potential therapeutic target.

1. Introduction

Cholangiocarcinoma (CCA) constitutes a rare and diverse group of malignancies arising from the biliary tree. Depending on their anatomical position, CCAs are divided into three subtypes: intrahepatic, perihilar and distal. The heterogeneous histogenesis of CCA may originate from hepatic progenitor cells, cholangiocytes, hepatocytes and liver

stem cells [1,2]. Moreover, their clinical manifestations, natural history, risk factors, and genomics can interfere with the chemotherapy response. Despite many advances in the field, the mechanisms of biliary carcinogenesis remain poorly understood [2,3].

Cholangiocarcinogenesis is orchestrated by a complex interaction of ligands, such as proinflammatory cytokines and growth factors. Immunohistochemical (IHC) studies have shown that growth factor receptors

Abbreviations: ITPRs, inositol 1,4,5-trisphosphate receptors; ITPR3, inositol 1,4,5-trisphosphate receptor type 3; InsP3, inositol 1,4,5-trisphosphate; EGFR, epidermal growth factor receptor; S100A4, S100 calcium-binding protein A4; CA 19-9, carbohydrate antigen; CCA, cholangiocarcinoma; NMIIA, nonmuscle myosin IIA.

* Correspondence to: Department of General Pathology, Instituto de Ciências Biológicas, Bloco C3, Sala 102, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627, Belo Horizonte, MG 31270-901, Brazil.

E-mail address: cassali@icb.ufmg.br (G.D. Cassali).

¹ Contributed equally.

<https://doi.org/10.1016/j.bioph.2021.112403>

Received 16 August 2021; Received in revised form 31 October 2021; Accepted 3 November 2021

Available online 16 November 2021

0753-3322/© 2021 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license

(<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

are overexpressed in samples of human CCA [4]. Epidermal growth factor receptor (EGFR), a tyrosine kinase receptor encoded by proto-oncogenes, has been reported to play a key role in the cell cycle, cell migration, and angiogenesis [5]. EGFR overexpression is implicated in CCA carcinogenesis, with a high expression level in the intrahepatic subtype [6]. EGFR activation by its ligand EGF also activates Ca^{2+} signaling via inositol 1,4,5-trisphosphate (InsP3), activating inositol 1,4,5-trisphosphate receptors (ITPRs) [7].

Ca^{2+} signaling pathways can regulate cellular processes such as tumor growth, cell proliferation, apoptosis, cell migration, gene transcription and necrosis. In cholangiocytes, Ca^{2+} release into the cytosol mainly occurs through the type 3 inositol 1,4,5-trisphosphate receptor (ITPR3) [8–11]. Previous work has demonstrated that this isoform is involved in CCA biology [12]. Furthermore, ITPR3 expression is involved in the pathogenesis of other malignancies, and its overexpression is correlated with other types of human cancer [13–15].

The effects of intracellular calcium are mediated by calcium-binding proteins that have been related to a poor prognosis and tumor aggressiveness in patients with different types of carcinoma, including colorectal, esophageal, bladder, pancreatic, gastric, and breast cancers [16–18]. For example, the protein S100A4, a calcium-binding protein containing two EF-hand domains, has been recognized to play a key role in tumor progression and metastasis [19,20]. This protein regulates a wide range of intracellular and extracellular biological effects, including cell proliferation, extracellular matrix remodeling, cell detachment, and angiogenesis [21,22]. For example, S100A4 interacts with the

C-terminus region of nonmuscle myosin IIA (NMIIA), causing filament disassembly, which is correlated with the increased metastatic potential of tumoral cells [23]. Previous work demonstrated S100A4 expression as a useful marker for predicting the progression, metastasis and prognosis of CCA as a metastasis-related gene [20]. Recently, S100A4 expression was detected in intrahepatic CCA, and the nuclear expression of S100A4 was identified as a strong predictor of metastasis and reduced survival after resection [20,22].

This study aimed to investigate the IHC expression of ITPR3, S100A4 and EGFR and their correlation with the clinicopathological features of intra- and extrahepatic CCAs. The association between ITPR3, S100A4 and EGFR expression and the postoperative survival of CCA patients was evaluated. Furthermore, it was demonstrated that EGF mediate calcium signals via ITPR3.

2. Materials and methods

2.1. Patient selection and anatomopathological study

A total of 59 samples were collected between January 2008 and March 2021 from subjects who underwent curative surgical resection with a histological diagnosis of CCA. Data regarding sex, age, history of smoking or alcoholism, localization, anatomic origin, CA 19-9 (carbohydrate antigen), histological type, tumor stage, angiovascular invasion, surgical margin and survival after treatment were collected. Classification and staging followed the TNM pattern of the American Joint Cancer

Table 1
Relationship between ITPR3, S100A4, EGFR and clinicopathological features in human cholangiocarcinoma cases.

Clinical features	Cases n	ITPR3		p	S100A4		p	EGFR		p
		Negative	Positive		Negative	Positive		Negative	Positive	
Gender										
Male	32	10	22		29	3		22	10	
Female	25	5	20	0.339	23	2	0.856	17	8	0.952
Age (years)										
≤ 60	27	5	22		24	3		17	10	
> 60	30	10	20	0.255	28	2	0.554	22	8	0.400
Smoking										
Yes	18	3	15		16	2		13	5	
No	37	10	27	0.396	34	3	0.716	24	13	0.585
Alcohol use										
Yes	16	4	12		15	1		12	4	
No	41	11	30	0.888	37	4	0.674	27	14	0.504
CA 19-9										
≤ 37 U/ml	12	7	5		12	0		9	3	
> 37 U/ml	24	6	18	0.049	22	2	0.375	14	10	0.326
Localization										
Intrahepatic	14	6	8		14	0		7	7	
Extrahepatic	43	9	34	0.106	38	5	0.182	32	11	0.088
Histology										
Papillary	15	4	11		14	1		10	5	
Others	42	11	31	0.971	38	4	0.737	29	13	0.865
Angiovascular invasion										
Positive	42	10	32		37	5		28	14	
Negative	15	5	10	0.472	15	0	0.162	11	4	0.634
Histological grade										
G1	14	2	12		14	0		12	2	
G2	38	12	26		35	3		25	13	
G3	5	1	4	0.429	3	2	0.024	2	3	0.140
Lymph node metastasis										
Positive	23	2	21		18	5		15	8	
Negative	28	10	18	0.024	28	0	0.009	20	8	0.634
T stage										
T1+T2	34	9	25		33	1		26	8	
T3+T4	23	6	17	0.974	19	4	0.058	13	10	0.112
TNM stage										
I+II	31	9	22		30	1		25	6	
III+IV	25	6	19	0.673	21	4	0.096	14	11	0.046
Surgical margin										
Positive	22	8	14		18	4		15	7	
Negative	35	7	28	0.172	34	1	0.047	24	11	0.975

Committee/Union for International Cancer Control [24,25]. To adjust for possible effects on survival related to surgical complications rather than tumor prognosis, subjects who died during the first 30 days after surgery were excluded; thus, the follow-up period started 30 days after tumor resection. The follow-up period ranged from 2 to 60 months (median: 21.78 months). The relationships between ITPR3, S100A4 and EGFR and the clinicopathological features of human CCA are reported in Table 1. The Institutional Ethics Committee approved this research (reference number: CAAE - 37156714.6.0000.5149).

2.2. IHC staining

The primary antibodies used for the IHC analysis were anti-EGFR (1:100, clone 31G7, Invitrogen, California, USA), ITPR3 (1:100, monoclonal, BD Biosciences, Rockville, MD, USA) and S100A4 (1:200, polyclonal, Invitrogen). IHC staining was performed as previously described, with minor modifications [26–28]. In brief, for ITPR3 and S100A4 staining, 4 μ m sections of primary tumors were mounted onto silanized slides, and formalin-fixed paraffin-embedded (FFPE) tissue sections were dewaxed, rehydrated, and unmasked in Trilogy solution (Cell Marque, Koclin, CA, USA) with pressurized heating (125 °C) for 20 min according to the manufacturer's instructions. Enzymatic recovery of EGFR was performed using 0.1% pepsin in 10 mM HCl (Sigma-Aldrich, St. Louis, MO, USA) at 37 °C for 30 min. Slides were dewaxed in xylene (Sigma-Aldrich), and endogenous peroxidase activity was quenched with 3% H₂O₂ in methanol (Sigma-Aldrich). Subsequently, the slides were covered with serum-free protein block (Dako, Santa Clara, CA, USA) for 30 min and then incubated with the primary antibodies (EGFR, ITPR3 and S100A4) overnight at 4 °C. A peroxidase-based detection system, Novolink™ Polymer (Leica Biosystems Newcastle Ltd., Newcastle, UK), was applied manually. Immunoreactivity was visualized by incubating the slides with 3,3'-diaminobenzidine (Lab Vision DAB substrate system; Lab Vision, Fremont, California, USA) for 2 min. Negative controls were prepared by omitting the primary antibody. Nontumor adjacent liver tissue was used as a positive control.

2.3. IHC scoring

Two independent observers evaluated the degree of immunostaining on the sections in a blinded manner. Five high-power fields (40 \times) from each section were randomly selected to evaluate the percentage of immunostained tumor cells and staining intensity. EGFR expression was assessed in CCA samples using the scores defined according to the consensus of the American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP; Wolff et al.) as follows: 0 = no membrane staining or incomplete and faint/barely perceptible membrane staining in \leq 10% of tumor cells, 1 = incomplete and faint/barely perceptible membrane staining in \geq 10% of tumor cells, 2 = incomplete and/or weak/moderate membrane staining in $>$ 10% of tumor cells or complete and intense membrane staining in \leq 10% of tumor cells, and 3 = complete and intense membrane staining in $>$ 10% of tumor cells. In our study, specimens with scores of 0, 1 and 2 were regarded as low/negative, and those with a score of 3 were regarded as high/positive [29, 30].

The scoring method used by Silveira et al. for prostaglandin G/H synthase 2 (COX2) was adapted for ITPR3 and S100A4 scoring [31,32]. The number of ITPR3- and S100A4-positive cells was evaluated semi-quantitatively, with the distribution score defined by the estimated percentage of positive cells in five fields at 40 \times magnification as follows: 0 = absence, 1 = fewer than 10% stained cells, 2 = between 10% and 30%, 3 = between 31% and 60%, and 4 = more than 61% stained cells. For staining intensity, the values ranged from 0 to 3 as follows: 0 = absence, 1 = weak staining, 2 = moderate staining, and 3 = strong staining. The distribution score and intensity were multiplied to obtain a total score, which ranged from 0 to 12. To evaluate S100A4 expression, staining in the cytoplasm and/or nuclei was considered positive.

2.4. Bioinformatic analysis of proteomics data

The mass spectrometry proteomics data analyzed were deposited into the ProteomeXchange Consortium via the PRIDE partner repository under dataset identifier PXD010294. The normalized abundance of ITPR3 (protein ID: Q14573) was analyzed from the dataset 1813003-Quantification-allgroups-withoutHCC-protein-measurement.xlsx [33, 34].

2.5. Cell culture

The cholangiocarcinoma cell lines MzChA-1 WT and MzChA-1 ITPR3-KO were kindly provided by Dr. Michael H. Nathanson (Yale University, CT, USA). The ITPR3 knockout MzChA-1 cells were established by using the CRISPR/Cas9 system, as described previously [12]. The MzChA-1 WT and MzChA-1 ITPR3-KO cell lines were cultured in MEM-Alpha medium supplemented with 10% Fetal Bovine Serum (FBS) and 100 units/ml penicillin, and 100 μ g/ml streptomycin (Invitrogen). Cells were maintained at 37 °C in an atmosphere of 5% of CO₂ atmosphere incubator.

2.6. Immunoblot analysis

Western blotting was performed and detected as described previously [7]. In brief, MzChA-1 whole-cell extracts were obtained from homogenized samples by using a lysis buffer (150 mM NaCl, 1 mM EDTA, 20 mM Tris-HCl, pH 8.0, 0.5% Nonidet P-40% and 1% of protease inhibitor cocktail, Sigma-Aldrich). Lysates were centrifuged at 16,000g for 10 min at 4 °C and quantified using the Bradford assay reagent from Sigma-Aldrich. Extracts of protein (30 μ g) was separated by electrophoresis on a denaturing 10% polyacrylamide-sodium dodecyl sulfate gel and transferred to a polyvinylidene difluoride membrane (Bio-Rad, Hercules, CA, USA). The membranes were blocked for 1 h in Tris-buffered saline (TBS) containing 5% (w/v) nonfat dry milk and 0.05% Tween-20 and incubated with specific anti-ITPR3 mouse monoclonal antibody (1:500, BD Biosciences) in TBS containing 5% (w/v) nonfat dry milk and 0.05% Tween-20. As a loading control, the membranes were reprobated with anti-GAPDH (1:4000; Santa Cruz, TX, USA). After washing, the membranes were incubated with a horseradish peroxidase-conjugated anti-mouse secondary antibody (1:2000; Sigma Aldrich). Immunoreactive bands were visualized using an enhanced chemiluminescence reagent (ECL Plus; GE Healthcare Life Sciences, Piscataway, NJ, USA). The western blot repeats are presented in Supplementary Fig. 2.

2.7. Cytosolic calcium signaling

ITPR3-KO-MzChA-1 or control-MzChA-1 (WT) cells were plated and cultured on 35 mm glass-bottom dishes (MatTex, Ashland, MA, USA) for 24 h. Cells were serum-starved (6–10 h) prior EGF stimulus. Then, cells were loaded with 5 μ M of Fluor-4 AM (Thermo Fisher Scientific) for 15 min at 37 °C in HEPES-buffered solution. Dishes were placed on the stage of the LSM 880 Zeiss Confocal microscope at 40 \times magnification, and cells were kept on HEPES-buffered solution during imaging. Cells were stimulated with EGF 200 ng/ml. Fluor-4 AM fluorescence images were collected at a rate of 5 frames/second. Changes in fluorescence F were normalized by the initial fluorescence (F_0) and were expressed as (F/F_0) \times 100%. Cells maximum peak responses were quantified by using ImageJ software (NIH) [11].

2.8. Immunofluorescence

Immunofluorescence imaging were performed as described previously [7,35]. In brief, MzChA-1 cells were double labeled with a mouse monoclonal anti-ITPR3 (1:200, BD Biosciences) and a rabbit polyclonal anti- nonmuscle myosin IIA (NMIIA) (1:200, Thermo Scientific, Austin,

TX, USA) overnight at 4 °C and then incubated with secondary antibodies conjugated to Alexa Fluor 488 or 546 (Thermo Scientific). Hoechst 33342 (Thermo Scientific) was used as a marker for the nuclear compartment. The negative control was included in all reactions by omitting primary antibodies. Images were collected using a Leica GSD/TIRF HP microscope with a HC PL APO × 100, 1.47 NA oil objective lens. Images were deconvolved using the 3D deconvolution module available in the LAS X software using 10 interactions. LAS X 3D analysis module was used to quantify the number of clusters of ITPR3 that come into contact with NMIIA.

2.9. Statistical analysis

Differences in the IHC score and tumor marker levels depending on location were analyzed using the Kruskal-Wallis test and Mann-Whitney *U*-test. Statistical analysis of survival curves and Cox proportional hazards regression model were carried out using the survival and survminer packages of RStudio software (version 1.4.1717; running R version: 4.1.0). Chi-square and Fisher's exact tests were used to analyze the correlation between ITPR3, S100A4 and EGFR expression and the clinicopathological characteristics of CCA patients. According to the Kaplan–Meier survival analysis, the log-rank test was used to compare the overall survival rate of patients. Multivariate analyses were performed using the Cox proportional hazards regression model. $P < 0.05$ was considered statistically significant, except as otherwise stated. The significance of changes in maximum peak-calcium levels and western blot experiments were determined by Student's *t*-test, using GraphPad Prism software. Data are represented as mean ± S.D.

3. Results

3.1. Expression of ITPR3, S100A4 and EGFR in primary CCA

First, the relationship of ITPR3, S100A4 and EGFR expression in CCA was examined in liver samples from patients with intrahepatic ($n = 17$), perihilar ($n = 29$) or distal ($n = 17$) CCA. Histological diagnoses were established based on the examination of hematoxylin-eosin (H&E)-stained specimens (Fig. 1A–D). The rates of high ITPR3, EGFR and S100A4 expression were 73.6%, 31.58% and 8.7%, and the rates of low expression were 26.32%, 68.42% and 91.23%, respectively (Fig. 2). Representative images of high/positive and low/negative staining for each protein are shown in Fig. 2. Next, relative ITPR3 expression was examined according to the anatomical origin of the tumor. IHC labeling

of ITPR3 increased when comparing control bile ducts with intrahepatic, perihilar and distal CCAs ($p < 0.05$ and $p < 0.0001$, respectively) (Fig. 3B). No labeling difference was observed between intrahepatic versus perihilar CCA (Fig. 3B). This result was confirmed when comparing ITPR3 expression according to the IHC score and proteomics quantification (Fig. 3C and D). Increased ITPR3 expression in distal CCA compared with intrahepatic CCA was confirmed by the IHC score and proteomics quantification ($p < 0.05$) (Fig. 3C and D). Proteomic analysis showed that S100A4 expression was increased in perihilar compared with intrahepatic and distal CCA ($p < 0.05$) (see Supplementary Fig. 1A). No difference was observed in EGFR expression comparing the three anatomical regions (see Supplementary Fig. 1B). The reference for the mass spectrometry data used for the analysis is presented in methods Section 2.4. Nontumor liver tissue was used as a positive control. The IHC staining of liver sections from controls showed that ITPR3 expression in cholangiocytes was concentrated at the bile duct apical area, as has been described previously [9,12]. Together, these results demonstrate that ITPR3 expression is increased in CCA, and its overexpression is especially pronounced in patients with distal CCA.

3.2. Correlation between ITPR3, S100A4 and EGFR expression and clinicopathological characteristics

The chi-square analysis showed that positive ITPR3 expression was correlated with a CA 19-9 value > 37 U/ml ($P = 0.049$) and lymph node metastasis ($P = 0.024$). S100A4-positive expression was correlated with a high histological grade ($P = 0.024$), lymph node metastasis ($P = 0.009$) and surgical margin ($P = 0.047$). EGFR-positive expression was correlated with TNM stage ($P = 0.046$). Other factors, including sex, age, smoking and alcohol use, localization, histology, angiovascular invasion and T stage, showed no significant correlation with any of the 3 proteins analyzed (Table 1).

Correlations between ITPR3, S100A4 and EGFR were explored with Fisher's exact test. The expression of ITPR3 was correlated with the expression of S100A4 ($p = 0.049$). On the other hand, there was no significant correlation between the expression of EGFR and the expression of the other proteins (Table 2).

3.3. Survival analysis

Kaplan–Meier survival analysis was performed on the 49 patients who survived for more than one month after surgery (Fig. 4A). During the follow-up period (1–60 months), a total of 31 patients died (63.2%).




Fig. 1. Liver histology from CCA patients and controls. Representative photomicrographs of liver specimens from controls and patients with intrahepatic, perihilar and distal CCA stained with hematoxylin and eosin (H&E). (A) Liver section showing a normal hepatic parenchyma with one normal-appearing portal tract. (B) Section from an intrahepatic CCA showing many glandular structures with round to irregular profiles. (C) Section from a perihilar CCA showing a papillary type of growth. (D) Section from a distal CCA showing a papillary type of growth. Micrographs represent observations from 15, 29 and 15 patients in each category. Scale bars = 100 μ m.




Fig. 2. Representative images of high/positive and low/negative expression (IHC staining). High/positive expression of ITPR3 (73.6%), S100A4 (8.7%) and EGFR (31.58%) and low/negative expression of ITPR3 (26.32%), S100A4 (91.23%) and EGFR (68.42%). Scale bars = 100 μm.




Fig. 3. ITPR3 staining is increased in cholangiocytes of patients with distal CCA. (A) Representative immunohistochemical (IHC) staining of ITPR3 in liver specimens from control bile ducts (black arrows) and patients with intrahepatic, perihilar and distal CCAs shows that ITPR3 staining is more intense in liver samples from CCA patients. Scale bars = 100 μm. (B) Quantitative analysis of the intensity of ITPR3 staining in IHC images. Images are representative of observations from 10 patients (10 images per patient), * $p < 0.0001$. (C) ITPR3 expression versus the anatomical origin of the tumor, $p < 0.05$. (D) ITPR3 expression abundance by bioinformatic analysis of proteomics data, $p < 0.05$.

Table 2
Correlation between ITPR3, S100A4 and EGFR expression in human cholangiocarcinoma.

	S100A4	EGFR
ITPR3 correlation coefficient	0.262	0.017
p	0.049	0.898
S100A4 correlation coefficient		-0.040
p		0.767

The median survival time based on 49 subjects was 29 months (95% confidence interval [CI] = 18–43). As shown in Fig. 4, for subjects with low and high ITPR3 expression, the median survival times were 40 and 19 months ($p = 0.4715$) (Fig. 4B). The median survival times were 19 and 40 months ($p = 0.2773$) when comparing patients with low versus high EGFR expression (Fig. 4C) and 30 and 18 months ($p = 0.1948$) for patients with low versus high S100A4 expression (Fig. 4D). The overall survival rates comparing the high and low expression levels between the 3 proteins showed no difference under study.

3.4. Multivariate analysis of the prognosis of patients with CCA

Multivariate analyses using the Cox proportional hazards regression model were performed to assess independent prognostic factors for CCA (Fig. 5). The four significant factors (CA 19-9, lymph node metastasis, T stage, and TNM stage) identified in the univariate analysis were analyzed. The multivariate analysis of CA, T, N, Stage and S100A4 and EGFR scores showed that TNM stages III+IV and EGFR expression (HR: 55.60; $p = 0.005$, HR: 13.36; $p = 0.028$; Fig. 5A) were independent prognostic factors for overall survival (see model 1). According to model 2 (CA, T, N, Stage and ITPR3 and EGFR), the higher TNM stages (III+IV) were more significant than the lower TNM stages (I+II) (HR: 14.94; $p = 0.012$) (Fig. 5B). The multivariate analysis of CA, T, N, Stage, ITPR3, S100A4 and EGFR scores on model 3 also demonstrated the significance of TNM stages III+IV (HR: 47.07; $p = 0.01$) when comparing EGFR

high/positive expression with low/negative EGFR expression (HR: 13.56; $p = 0.042$) (Fig. 5C).

3.5. EGF induces Ca^{2+} signaling in cholangiocarcinoma cell line

To demonstrate that epidermal growth factor (EGF) mediate calcium signals via ITPR3, a MzChA-1 cholangiocarcinoma cell line knockout for ITPR3 was used. This CRISPR/Cas9 knockout cell was characterized in detail previously [12]. First, we confirmed a reduction of $96.8 \pm 1.4\%$ of ITPR3 expression levels by western blot in MzChA-1 Knockout (KO) compared with the MzChA-1 wild type (WT) cell ($n = 3$; $P < 0.0001$) (Fig. 6A and B). Next, cells were loaded with $5 \mu\text{M}$ of Fluo-4 AM to examine EGF induced- Ca^{2+} signaling. Cells were observed by time-lapse confocal microscopy and after 1 min of imaging MzChA-1 WT or MzChA-1 KO were stimulated with 200 ng/ml of EGF. The maximum peak analyses demonstrated a reduction of $229.5 \pm 18.5\%$ in KO cells compared with WT ($n = 34$ WT or 28 KO cells, $P < 0.0001$) (Fig. 6C and D). These findings demonstrate that EGF induces Ca^{2+} signals that are mediated via ITPR3 in this cholangiocarcinoma cell line.

3.6. ITPR3 colocalizes with nonmuscle myosin IIA

The expression of S100A4 was correlated with the expression of ITPR3. It was demonstrated that NMIIA interacts with S100A4 [23]. We investigate if ITPR3 colocalizes with NMIIA. First, was performed immunofluorescence followed by 3D imaging to visualize the colocalization of ITPR3 with NMIIA in MzChA-1 WT cells. To observe the colocalization of these proteins in 3D orthogonal projections were used (Fig. 7A). The xy and xz projections showed that NMIIA colocalizes with ITPR3. ITPR3 was accumulated at the perinuclear regions of the cells (Fig. 7B). To confirm this colocalization, 3D rendering was performed using the LAS X 3D analysis to quantify the number of clusters of ITPR3 that come into contact with NMIIA clusters (only contact points are shown in white, Fig. 7C). Quantification of contact points in 3D




Fig. 4. Probability of survival in CCA patients following resection. (A) Kaplan-Meier survival curve estimates for CCA patients with low/negative and high/positive ITPR3, EGFR and S100A4 expression after surgical resection. (B) For ITPR3, the median survival times were 40 and 19 months ($p = 0.4715$). (C) For EGFR, the median survival times were 19 and 40 months ($p = 0.2773$). (D) For S100A4, the median survival times were 30 and 18 months ($p = 0.1948$).




Fig. 5. Multivariate analysis using the Cox proportional hazards model. (A-B and C) shows the proposed models. The global p values (log-rank) are 0.049139, 0.03732, and 0.036317, respectively.




Fig. 6. EGF induces calcium signaling in a cholangiocarcinoma cell line. Panel (A,B) show a representative immunoblot and quantitative analysis of total ITPR3 expression in MzChA-1 WT and MzChA-1 KO cells ($n = 3$, $P < 0.0001$). (C) Representative confocal images of MzChA-1 WT and MzChA-1 KO cells loaded with $5 \mu\text{M}$ Fluo-4 AM to monitor Ca^{2+} signaling in response to 200 ng/ml EGF. (D) The bar graph shows the maximum peak response analyses and it demonstrates a reduction of $229.5 \pm 18.5\%$ in KO cells compared with WT ($n = 34$ WT or 28 KO cells, $P < 0.0001$). Values are mean \pm S.D. of the maximum peak Fluo-4 AM fluorescence attained during the observation period. Results are expressed as % of baseline as described in materials and methods.

demonstrated that $20.2 \pm 3.6\%$ ($n = 3$) of the ITPR3 clusters come in contact with NMIIA. These results demonstrate that ITPR3 colocalizes with NMIIA.

4. Discussion

CCA is characterized by a poor prognosis, early invasion and widespread metastasis. However, there is still a lack of accurate noninvasive biomarkers to diagnose and estimate the prognosis of patients with CCA. Surgical resection remains the main potentially curative treatment for all three disease subtypes, and only a small percentage of patients are eligible. Thus, the investigation of new markers underlying the progression of CCA is important for diagnosis and therapy [1,2,36].

Here, we studied the expression of EGFR, ITPR3 and S100A4 in resected human CCA samples and correlated the clinical outcomes with these three proteins. A previous study demonstrated that EGFR

expression in CCA was associated with tumor progression and recurrence [37]. The EGFR family is known as a tyrosine-protein kinase family involved in many cellular processes by activating several downstream pathways [7,38]. Activated EGFR can initiate intracellular signals for cell proliferation, migration, adhesion and oncogenesis [26,38,39]. Increased EGFR expression and mutations in its gene are associated with neoplasms such as breast cancer, glioblastomas, non-small-cell lung cancer and head and neck squamous cell carcinoma [38]. EGFR family proteins are used as potential biomarkers for disease prognosis and progression in several tumors [40–42].

In this work, EGFR expression was considered positive in 31.58% of cases. The univariate analysis showed a higher expression rate in tumors in advanced stages, occurring in 19.6% of stage III + IV tumors versus 10.7% of stage I + II tumors ($p = 0.046$), translating characteristics of an aggressive phenotype in the presence of invasive disease. However, in our study, EGFR low/negative expression using the Cox proportional




Fig. 7. The ITPR3 colocalizes with nonmuscle myosin IIA. Immunofluorescence representative images of double-labeled MzChA-1 WT cells with ITPR3 and NMIIA, respectively. ITPR3 receptor labeling is in green, NMIIA labeling is in red and the nuclei are stained in blue with Hoechst. (A) Orthogonal sections of three-dimensional (3D) reconstruction were used to demonstrate that ITPR3 colocalizes with NMIIA. At the top right – the 3D projection, at the bottom left – the clipping plane with a view from the front, at the top left – the clip plane with a view from the top and at the bottom right – the clip plane with a view from the left. Images were reconstructed and rendered in 3D to confirm that ITPR3 interacts with NMIIA. Panel B shows the processed representative images. Image C displays in white only the contact points (see white arrows) between ITPR3 and NMIIA of cell presented in panel B. Scale bars = 5 or 10 μm .

hazards ratio showed that the risk of CCA increased 13.56 in patients with low EGFR expression versus those with high EGFR expression (Fig. 5C, $p = 0.042$). One hypothesis is that high EGFR expression is more important in tumors reaching the advanced stages.

CCA is classified into three subgroups according to its pathologic characteristics and stages. Depending on the location, CCAs have different degrees of invasion into adjacent structures, which may also influence prognosis [43]. The anatomical location implies different survival outcomes, although EGFR expression displayed no significant difference between the three locations, as previously described by our group [44].

EGFR activation by EGF also activates Ca^{2+} signaling via InsP3, activating ITPRs, and this signaling has been implicated in tumor growth [7]. Under normal conditions, ITPR3 plays an important role in mediating cholangiocyte bicarbonate secretion [45]. ITPR3 is reported to be decreased under cholestatic conditions [46]. ITPR3 is present and concentrated in the apical region of human and rodent bile duct epithelia [9,45]. The type 3 ITPR is the principal isoform in

cholangiocytes, and new evidence suggests that this isoform may play a particularly important role in cancer [9,12]. Previous work has shown that ITPR3 expression is involved in the pathogenesis of hepatocellular carcinoma [47]. It is also associated with colorectal carcinoma aggressiveness [14]. Ueasilamongkol et al. reported ITPR3 overexpression in both intrahepatic ($n = 4$) and hilar ($n = 3$) CCAs [12]. Our study examined ITPR3 expression in a larger number of patients ($n = 59$) with clinicopathological data according to the anatomic origins of the three types of CCA. It was shown that EGF-induced calcium signaling in the CCA cell line was impaired in ITPR3 KO cells suggesting that EGF mediate InsP3-Ca^{2+} signaling via ITPR3.

We found that ITPR3 expression was increased in patients with distal CCA compared with intrahepatic CCA and normal bile ducts. High/positive ITPR3 scoring (by IHC staining) was found in 73.6% of cases. Depending on the anatomic origin of CCA, ITPR3 expression was increased in perihilar and distal CCAs compared to intrahepatic CCA. The bioinformatic analysis of an independent study showed that ITPR3 expression was abundant in patients with distal CCA, corroborating our

findings. High/positive ITPR3 expression significantly increased with the levels of the tumor marker CA 19-9 in 50% of patients ($p = 0.049$). Lymph node metastasis was high in 41.1% of cases ($p = 0.024$).

The effects of calcium rise via ITPR3 are mediated by calcium-binding proteins such as S100A4. This protein has been proposed as a useful marker for predicting the progression, metastasis and prognosis of CCA [20]. S100A4 is localized in the cytoplasm, nucleus, and extracellular space and is involved in many steps of the metastatic cascade, including cell motility, invasion, and angiogenesis [21]. Previous studies of S100A4 expression have reported that the overexpression of S100A4 may be correlated with tumor aggressiveness and a poor prognosis in other types of carcinoma [48,49]. In this study, S100A4-positive expression in primary CCA was confirmed in 8.7% of cases. However, previous results indicated that nuclear S100A4 was a strong predictor of metastasis and reduced survival after resection in patients with CCA [20]. In our study, we observed nuclear expression in only 3 cases. However, in most of our specimens, cytoplasmic expression was predominant, as observed by Zhang et al. [22]. Furthermore, the positive staining in specimens was not restricted only to tumor cells because highly expressed levels were also detected in tumor/stroma tissues. High/positive S100A4 expression was correlated with a high histological grade, lymph node metastasis and surgical margin. In addition, S100A4 is reported to interact with the C-terminus region of NMIIA, causing filament disassembly [23]. The present work evaluated the colocalization of ITPR3 with NMIIA in MzChA-1 cell line. Our findings demonstrated that ITPR3 colocalized with NMIIA. Thus, NMIIA represents a new interactor protein with ITPR3 and these proteins may form a complex with S100A4. New studies are necessary to confirm this hypothesis.

The development of targeted therapies for CCA is hindered by the heterogeneity of these tumors, and the rarity of cases compared to other solid tumors is still a challenge [50,51]. Some limitations to this kind of study, such as the limited size of samples (since it is a relatively rare disease), need to be considered. However, the current work was the first to investigate and provide evidence of relationships between ITPR3, S100A4 and EGFR expression and prognostic factors such as CA 19-9, TNM and lymph node metastasis. We also demonstrated increased ITPR3 protein expression in distal CCA, which was confirmed with the bioinformatic analysis. Further work will be necessary to better understand the factors involved in ITPR3 accumulation in CCA and to determine whether these factors can be investigated for therapeutic proposals.

5. Conclusions

Our results demonstrate that the elevated expression of ITPR3 is correlated with clinicopathological findings, such as CA 19-9, TNM stage and lymph node metastasis (N). Furthermore, the expression of ITPR3 and S100A4 was significantly correlated. ITPR3 expression is increased in CCA, and its overexpression is particularly pronounced in patients with distal CCA. The IHC scoring and bioinformatic analysis reinforced these observations. EGF mediates Ca^{2+} signaling via ITPR3 in a CCA cell line. Furthermore, ITPR3 colocalizes with NMIIA and these proteins may form a network with S100A4. In conclusion, ITPR3 and S100A4 are involved in the progression and pathogenesis of CCA and they may represent a new therapeutic target for CCA.

CRedit authorship contribution statement

MAR, GDC and VR participated in the coordination of the study. MAR wrote the final manuscript. DAG and MAR performed the statistical analyses. MAR and GDC participated in the experiments and helped with the IHC and HE imaging analyses. MAR and ALC performed the IHC experiments. GDC, DAG, ALC, MDS and MAR reviewed the entire manuscript. MAR, GDC, VR and DAG conceived and designed the study. GDC and MDS were responsible for the histopathological examination.

All authors read and approved the manuscript.

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

This study was supported by grants from the NIH (1R03TW008709), CNPq, FAPEMIG and CAPES. The funding sources had no role in manuscript writing; data collection, analysis, or interpretation; or any other aspect pertinent to the study. We thank Dr. Michael H. Nathanson that kindly providing the cholangiocarcinoma cell lines. The microscopy data shown in this study were obtained using microscopes at Centro de Aquisição e Processamento de Imagens (CAPI-ICB/UFGM)

Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at doi:10.1016/j.biopha.2021.112403.

References

- [1] S. Rizvi, S.A. Khan, C.L. Hallemeier, R.K. Kelley, G.J. Gores, Cholangiocarcinoma — evolving concepts and therapeutic strategies, *Nat. Rev. Clin. Oncol.* 15 (2018) 95–111, <https://doi.org/10.1038/nrclinonc.2017.157>.
- [2] J.M. Banales, J.J.G. Marin, A. Lamarca, P.M. Rodrigues, S.A. Khan, L.R. Roberts, V. Cardinale, G. Carpino, J.B. Andersen, C. Braconi, D.F. Calvisi, M.J. Perugorria, L. Fabris, L. Boulker, R. Macias, E. Gaudio, D. Alvaro, S.A. Grdilone, M. Strazzabosco, M. Marzoni, C. Coulouarn, L. Fouassier, C. Raggi, P. Invernizzi, J. C. Mertens, A. Moncsek, S. Rizvi, J. Heimbach, B.G. Koerkamp, J. Bruix, A. Forner, J. Bridgewater, J.W. Valle, G.J. Gores, Cholangiocarcinoma 2020: the next horizon in mechanisms and management, *Nat. Rev. Gastroenterol. Hepatol.* 17 (2020) 557–588, <https://doi.org/10.1038/s41575-020-0310-z>.
- [3] J.M. Banales, R.C. Huebert, T. Karlsen, M. Strazzabosco, N.F. LaRusso, G.J. Gores, Cholangiocyte pathobiology, *Nat. Rev. Gastroenterol. Hepatol.* 16 (2019) 269–281, <https://doi.org/10.1038/s41575-019-0125-y>.
- [4] J. Harder, O. Waiz, F. Otto, M. Geissler, M. Olschewski, B. Weinhold, H.E. Blum, A. Schmitt-Graeff, O.G. Opitz, EGFR and HER2 expression in advanced biliary tract cancer, *World J. Gastroenterol.* 15 (2009) 4511–4517, <https://doi.org/10.3748/wjg.15.4511>.
- [5] A. Mahipal, A. Kommalapati, S.H. Tella, A. Lim, R. Kim, Novel targeted treatment options for advanced cholangiocarcinoma, *Expert Opin. Invest. Drugs* 27 (2018) 709–720, <https://doi.org/10.1080/13543784.2018.1512581>.
- [6] Y. Pignochino, I. Sarotto, C. Peraldo-Neia, J.Y. Penachioni, G. Cavalloni, G. Migliardi, L. Casorzo, G. Chiorino, M. Risio, A. Bardelli, M. Aglietta, F. Leone, Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas, *BMC Cancer* 10 (2010) 631, <https://doi.org/10.1186/1471-2407-10-631>.
- [7] M.C. de Miranda, M.A. Rodrigues, A.C. de Angelis Campos, J.A.Q.A. Faria, M. Kunrath-Lima, G.A. Mignery, D. Schechtman, A.M. Goes, M.H. Nathanson, D. A. Gomes, Epidermal growth factor (EGF) triggers nuclear calcium signaling through the intranuclear phospholipase C δ -4 (PLC δ 4), *J. Biol. Chem.* 294 (2019) 16650–16662, <https://doi.org/10.1074/jbc.RA118.006961>.
- [8] K. Hirata, M.H. Nathanson, Bile duct epithelia regulate biliary bicarbonate excretion in normal rat liver, *Gastroenterology* 121 (2001) 396–406, <https://doi.org/10.1053/gast.2001.26280>.
- [9] K. Hirata, J.-F. Dufour, K. Shibao, R. Knickelbein, A.F. O'Neill, H.-P. Bode, D. Cassio, M.V. St-Pierre, N.F. Larusso, M.F. Leite, M.H. Nathanson, Regulation of Ca^{2+} signaling in rat bile duct epithelia by inositol 1,4,5-trisphosphate receptor isoforms, *Hepatology* 36 (2002) 284–296, <https://doi.org/10.1053/jhep.2002.34432>.
- [10] D.A. Gomes, M. Thompson, N.C. Souto, T.S. Goes, A.M. Goes, M.A. Rodrigues, et al., The type III inositol 1,4,5-trisphosphate receptor preferentially transmits apoptotic Ca^{2+} signals into mitochondria, *J. Biol. Chem.* (2005) 280, <https://doi.org/10.1074/jbc.M506623200>.
- [11] M.A. Rodrigues, D.A. Gomes, M.F. Leite, W. Grant, L. Zhang, W. Lam, Y.C. Cheng, A.M. Bennett, M.H. Nathanson, Nucleoplasmic calcium is required for cell proliferation, *J. Biol. Chem.* 282 (2007) 17061–17068, <https://doi.org/10.1074/jbc.M700490200>.
- [12] P. Ueasilomghol, T. Khamphaya, M.T. Guerra, M.A. Rodrigues, D.A. Gomes, Y. Kong, W. Wei, D. Jain, D.C. Trampert, M. Anantharayanan, J.M. Banales, L. R. Roberts, F. Farshidfar, M.H. Nathanson, J. Wearachayaphorn, Type 3 inositol 1,4,5-trisphosphate receptor is increased and enhances malignant properties in cholangiocarcinoma, *Hepatology* 71 (2020) 583–599, <https://doi.org/10.1002/hep.30839>.

- [13] S.S. Kang, K.-S. Han, B.M. Ku, Y.K. Lee, J. Hong, H.Y. Shin, A.G. Almonte, D. H. Woo, D.J. Brat, E.M. Hwang, S.H. Yoo, C.K. Chung, S.H. Park, S.H. Paek, E. J. Roh, S.J. Lee, J.Y. Park, S.F. Traynelis, C.J. Lee, Caffeine-mediated inhibition of calcium release channel inositol 1,4,5-trisphosphate receptor subtype 3 blocks glioblastoma invasion and extends survival, *Cancer Res.* 70 (2010) 1173–1183, <https://doi.org/10.1158/0008-5472.CCR-09-2886>.
- [14] K. Shibao, M.J. Fiedler, J. Nagata, N. Minagawa, K. Hirata, Y. Nakayama, Y. Iwakiri, M.H. Nathanson, K. Yamaguchi, The type III inositol 1,4,5-trisphosphate receptor is associated with aggressiveness of colorectal carcinoma, *Cell Calcium* 48 (2010) 315–323, <https://doi.org/10.1016/j.ceca.2010.09.005>.
- [15] M.L. Hedberg, G. Goh, S.I. Chiosea, J.E. Bauman, M.L. Freilino, Y. Zeng, L. Wang, B.B. Diegergard, W.E. Gooding, V.W. Lui, R.S. Herbst, R.P. Lifton, J.R. Grandis, Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma, *J. Clin. Investig.* 126 (2015) 169–180, <https://doi.org/10.1172/JCI82066>.
- [16] C. Xu, H. Chen, X. Wang, J. Gao, Y. Che, Y. Li, F. Ding, A. Luo, S. Zhang, Z. Liu, S100A14, a member of the EF-hand calcium-binding proteins, is overexpressed in breast cancer and acts as a modulator of HER2 signaling, *J. Biol. Chem.* 289 (2014) 827–837, <https://doi.org/10.1074/jbc.M113.469718>.
- [17] H. Chen, C. Xu, Q. Jin, Z. Liu, S100 protein family in human cancer, *Am. J. Cancer Res.* 2 (2014) 89–115, <https://www.ncbi.nlm.nih.gov/pubmed/24660101>.
- [18] T. Nedjadi, A. Evans, A. Sheikh, L. Barerra, S. Al-Ghamdi, L. Oldfield, W. Greenhalf, J.P. Neoptolemos, E. Costello, S100A8 and S100A9 protein form part of a paracrine feedback loop between pancreatic cancer cells and monocytes, *BMC Cancer* 18 (2018) 1255, <https://doi.org/10.1186/s12885-018-5161-4>.
- [19] C.K. Park, W.H. Jung, J.S. Koo, Expression of cancer-associated fibroblast-related protein differs between invasive lobular carcinoma and invasive ductal carcinoma, *Breast Cancer Res. Treat.* 159 (2016) 55–69, <https://doi.org/10.1007/s10549-016-3929-2>.
- [20] L. Fabris, M. Cadamuro, L. Moserle, J. Dziura, X. Cong, L. Sambado, G. Nardo, A. Sonzogni, M. Colledan, A. Furlanetto, N. Bassi, M. Massani, U. Cillo, C. Mescoli, S. Indraccolo, M. Rugge, L. Okolicinnyi, M. Strazzabosco, Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastatic colonization, *Hepatology* 54 (2011) 890–899, <https://doi.org/10.1002/hep.24466>.
- [21] K. Boye, G.M. Melandsmo, S100A4 and metastasis, *Am. J. Pathol.* 176 (2010) 528–535, <https://doi.org/10.2353/ajpath.2010.090526>.
- [22] X. Tian, Q. Wang, Y. Li, J. Hu, L. Wu, Q. Ding, C. Zhang, The expression of S100A4 protein in human intrahepatic cholangiocarcinoma: clinicopathologic significance and prognostic value, *Pathol. Oncol. Res.* 21 (2015) 195–201, <https://doi.org/10.1007/s12253-014-9806-6>.
- [23] B. Kiss, L. Kalmár, L. Nyitrai, G. Pál, Structural determinants governing S100A4-induced isoform-selective disassembly of nonmuscle myosin II filaments, *FEBS J.* 283 (2016) 2164–2180, <https://doi.org/10.1111/febs.13728>.
- [24] S.B. Edge, C.C. Compton, The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM, *Ann. Surg. Oncol.* 17 (2010) 1471–1474, <https://doi.org/10.1245/s10434-010-0985-4>.
- [25] M.B. Amin, F.L. Greene, S.B. Edge, C.C. Compton, J.E. Gershenwald, R. K. Brookland, L. Meyer, D.M. Gress, D.R. Byrd, D.P. Winchester, The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging, *CA Cancer J. Clin.* 67 (2017) 93–99, <https://doi.org/10.3322/canc.21388>.
- [26] J.A.Q.A. Faria, C. de Andrade, A.M. Goes, M.A. Rodrigues, D.A. Gomes, Effects of different ligands on epidermal growth factor receptor (EGFR) nuclear translocation, *Biochem. Biophys. Res. Commun.* 478 (2016) 39–45, <https://doi.org/10.1016/j.bbrc.2016.07.097>.
- [27] M.A. Rodrigues, C.O. Gamba, J.A.Q.A. Faria, E. Ferreira, A.M. Goes, D.A. Gomes, G.D. Cassali, Inner nuclear membrane localization of epidermal growth factor receptor (EGFR) in spontaneous canine model of invasive micropapillary carcinoma of the mammary gland, *Pathol. Res. Pract.* 212 (2016) 212–244, <https://doi.org/10.1016/j.prp.2015.11.017>.
- [28] M.A. Rodrigues, A.L. Caldeira-Brant, D.A. Gomes, T.L. Silveira, H. Chiarini-Garcia, G.D. Cassali, Characterization of neoplastic cells outlining the cystic space of invasive micropapillary carcinoma of the canine mammary gland, *BMC Vet. Res.* 17 (2021) 130, <https://doi.org/10.1186/s12917-021-02807-y>.
- [29] A.C. Wolff, M.E. Hammond, D.G. Hicks, M. Dowsett, L.M. McShane, K.H. Allison, D.C. Allred, J.M. Bartlett, M. Bilous, P. Fitzgibbons, W. Hanna, R.B. Jenkins, P. B. Mangu, S. Paik, E.A. Perez, M.F. Press, P.A. Spears, G.H. Vance, G. Viale, D. F. Hayes, O. American Society of Clinical, P. College of American, Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update, *J. Clin. Oncol.* 31 (2013) 3997–4013, <https://doi.org/10.1200/JCO.2013.50.9984>.
- [30] A.C. Wolff, M.E.H. Hammond, K.H. Allison, B.E. Harvey, L.M. McShane, M. Dowsett, HER2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary, *J. Oncol. Pract.* 14 (2018) 437–441, <https://doi.org/10.1200/JOP.18.00206>.
- [31] G.E. Lavalle, A.C. Bertagnoli, W.L.F. Tavares, G.D. Cassali, Cox-2 expression in canine mammary carcinomas, *Vet. Pathol.* 46 (2009) 1275–1280, <https://doi.org/10.1354/vp.08-VP-0226-CFL>.
- [32] T.L. Silveira, E.S. Veloso, I.N.N. Gonçalves, R.F. Costa, M.A. Rodrigues, G. D. Cassali, H.L. Del Puerto, L.Y. Pang, D.J. Argyle, E. Ferreira, Cyclooxygenase-2 expression is associated with infiltration of inflammatory cells in oral and skin canine melanomas, *Vet. Comp. Oncol.* 18 (2020) 727–738, <https://doi.org/10.1111/vco.12601>.
- [33] J.A. Vizcaíno, A. Csordas, N. Del-Toro, J.A. Duanes, J. Griss, I. Lavidas, G. Mayer, Y. Perez-Riverol, F. Reisinger, T. Ternent, Q.W. Xu, R. Wang, H. Hermjakob, 2016 update of the PRIDE database and its related tools, *Nucleic Acids Res.* 44 (2016) D447–D456, <https://doi.org/10.1093/nar/gkv1145>.
- [34] J. Le Faouder, E. Gigante, T. Léger, M. Albuquerque, A. Beaufrière, O. Soubrane, S. Dokmak, J.M. Canadroit, J. Cros, V. Paradis, Proteomic landscape of cholangiocarcinomas reveals three different subgroups according to their localization and the aspect of non-tumor liver, *Proteom. Clin. Appl.* 13 (2019), 1800128, <https://doi.org/10.1002/prca.201800128>.
- [35] C.C.F. Faraco, J.A.Q.A. Faria, M. Kunrath-Lima, M.C. Miranda, M.L.A. de Melo, A. Ferreira, M.A. Rodrigues, D.A. Gomes, Translocation of Epidermal Growth Factor (EGF) to the nucleus has distinct kinetics between adipose tissue-derived mesenchymal stem cells and a mesenchymal cancer cell lineage, *J. Struct. Biol.* 202 (2018) 61–69, <https://doi.org/10.1016/j.jsb.2017.12.007>.
- [36] S. Rizvi, G.J. Gores, Pathogenesis, diagnosis, and management of cholangiocarcinoma, *Gastroenterology* 145 (2013) 1215–1229, <https://doi.org/10.1053/j.gastro.2013.10.013>.
- [37] S. Padthaisong, M. Thanee, N. Namwat, V. Phetcharuburanin, P. Klanrit, N. Khuntkeo, A. Titapun, W. Lollome, A panel of protein kinase high expression is associated with postoperative recurrence in cholangiocarcinoma, *BMC Cancer* 20 (2020) 154, <https://doi.org/10.1186/s12885-020-6655-4>.
- [38] Y. Yarden, G. Pines, The ERBB network: at last, cancer therapy meets systems biology, *Nat. Rev. Cancer* 12 (2012) 553–563, <https://doi.org/10.1038/nrc3309>.
- [39] A.C. De Angelis Campos, M.A. Rodrigues, C. de Andrade, A.M. de Goes, M. H. Nathanson, D.A. Gomes, Epidermal growth factor receptors destined for the nucleus are internalized via a clathrin-dependent pathway, *Biochem. Biophys. Res. Commun.* 412 (2011) 341–346, <https://doi.org/10.1016/j.bbrc.2011.07.100>.
- [40] C.L. Arteaga, J.A. Engelman, ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics, *Cancer Cell* 25 (2014) 282–303, <https://doi.org/10.1016/j.ccr.2014.02.025>.
- [41] R. Briffa, I. Um, D. Faranti, Y. Zhou, A.K. Turnbull, S.P. Langdon, D.J. Harrison, Multi-scale genomic, transcriptomic and proteomic analysis of colorectal cancer cell lines to identify novel biomarkers, *PLoS One* 10 (2015), e0144708, <https://doi.org/10.1371/journal.pone.0144708>.
- [42] K. Miyata, F. Yotsumoto, S. Fukagawa, C. Kiyoshima, N.S. Ouk, D. Urushiyama, T. Ito, T. Katsuda, M. Kurakazu, R. Araki, A. Sanui, D. Miyahara, M. Murata, K. Shirota, H. Yagi, T. Takono, K. Kato, N. Yeagashi, K. Akazawa, M. Kuroki, S. Yasunaga, S. Miyamoto, Serum heparin-binding epidermal growth factor-like growth factor (HB-EGF) as a biomarker for primary ovarian cancer, *Anticancer Res.* 37 (2017) 3955–3960, <https://doi.org/10.21873/anticancer.11779>.
- [43] G. Ercolani, A. Dazzi, F. Giovinazzo, A. Ruzzenente, C. Bassi, A. Guglielmi, A. Scarpa, A. D’Errico, A.D. Pinna, Intrahepatic, peri-hilar and distal cholangiocarcinoma: three different locations of the same tumor or three different tumors? *Eur. J. Surg. Oncol. (EJSO)* 41 (2015) 1162–1169, <https://doi.org/10.1016/j.ejso.2015.05.013>.
- [44] R.V. Gomes, M.A. Rodrigues, J.B.S.R. Rodrigues, P.T. Vidigal, K.A. Damasceno, H. A. Lima, D.A. Gomes, C.J. Machado, V. Resende, Expression of epidermal growth factor receptor (EGFR) in cholangiocarcinomas: predictive factors and survival, *Rev. Colegiu Bras. Cir.* 45 (2018) 45, <https://doi.org/10.1590/0100-6991e-20181826>.
- [45] N. Minagawa, J. Nagata, K. Shibao, A.I. Masyuk, D.A. Gomes, M.A. Rodrigues, G. Lesage, Y. Akiba, J.D. Kaunitz, B.E. Ehrlich, N.F. Larusso, M.H. Nathanson, Cyclic AMP regulates bicarbonate secretion in cholangiocytes through release of ATP into bile, *Gastroenterology* 133 (2007) 1592–1602, <https://doi.org/10.1053/j.gastro.2007.08.020>.
- [46] K. Shibao, K. Hirata, M.E. Robert, M.H. Nathanson, Loss of inositol 1,4,5-trisphosphate receptors from bile duct epithelia is a common event in cholestasis, *Gastroenterology* 125 (2003) 1175–1187, [https://doi.org/10.1016/S0016-5085\(03\)01201-0](https://doi.org/10.1016/S0016-5085(03)01201-0).
- [47] M.T. Guerra, R.M. Florentino, A. Franca, A.C. Lima Filho, M.L. dos Santos, R. C. Fonseca, F.O. Lemos, M.C. Fonseca, E. Kruglov, A. Menzone, B. Njei, J. Gibson, F. Guan, Y.C. Cheng, M. Ananthanarayanan, J. Gu, J. Jiang, H. Zhao, C.X. Lima, P. T. Vidigal, A.G. Oliveira, M.H. Nathanson, M.F. Leite, Expression of the type 3 *InsP* 3 receptor is a final common event in the development of hepatocellular carcinoma, *Gut* 68 (2019) 1676–1687, <https://doi.org/10.1136/gutjnl-2018-317811>.
- [48] Y.-Y. Wang, Z.-Y. Ye, Z.-S. Zhao, H.-Q. Tao, Y.-Q. Chu, High-level expression of S100A4 correlates with lymph node metastasis and poor prognosis in patients with gastric cancer, *Ann. Surg. Oncol.* 17 (2010) 89–97, <https://doi.org/10.1245/s10434-009-0722-z>.
- [49] N. Tsukamoto, S. Egawa, M. Akada, K. Abe, Y. Saiki, N. Kaneko, S. Yokoyama, K. Shima, A. Yamamura, F. Motoi, H. Abe, H. Hayashi, K. Ishida, T. Moriya, T. Tabata, E. Kondo, N. Kanai, Z. Gu, M. Sunamura, M. Unno, A. Horii, The expression of S100A4 in human pancreatic cancer is associated with invasion, *Pancreas* 42 (2013) 1027–1033, <https://doi.org/10.1097/MPA.0b013e31828804e7>.
- [50] J.S. Voss, L.M. Holtegaard, S.E. Kerr, E.G. Fritcher, L.R. Roberts, G.J. Gores, J. Zhang, W.E. Highsmith, K.C. Halling, B.R. Kipp, Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions, *Hum. Pathol.* 44 (2013) 1216–1222, <https://doi.org/10.1016/j.humpath.2012.11.006>.
- [51] J.M. Banales, V. Cardinale, G. Carpino, M. Marzoni, J.B. Andersen, P. Invernizzi, G.E. Lind, T. Folseraas, S.J. Forbes, L. Fouassier, A. Geier, D.F. Calvisi, J. C. Mertens, M. Trauner, A. Benedetti, L. Maroni, J. Vaquero, R.I. Macias, C. Raggi, M.J. Perugorria, E. Gaudio, K.M. Boberg, J.J. Marin, D. Alvaro, Cholangiocarcinoma: current knowledge and future perspectives consensus

M.A. Rodrigues et al.

Biomedicine & Pharmacotherapy 145 (2022) 112403

statement from the European Network for the Study of Cholangiocarcinoma (ENS-

CCA), *Nat. Rev. Gastroenterol. Hepatol.* 13 (2016) 261–280, <https://doi.org/10.1038/nrgastro.2016.51>.